











Title of Document: RNA INTERFERENCE MEDIATED 
SUPPRESSION OF TN-CASPASE-1 AS A 
MEANS OF INVESTIGATING APOPTOSIS 
AND IMPROVING RECOMBINANT 
PROTEIN PRODUCTION IN TRICHOPLUSIA 
NI CELLS 
  
 Colin G. Hebert, Doctor of Philosophy in 
Bioengineering 
  
Directed By: Dr. William E. Bentley, Professor and Chair, 
Fischell Department of Bioengineering 
 
 
The baculovirus expression system has proven to be a robust and versatile 
system for recombinant protein production in insect cells.  A wide range of promoters 
is available for the facile expression of transgenes, and yields of up to 50% of total 
protein have been reported.  However, in many cases production is decreased as a 
result of proteases and host cell apoptosis.  To combat this problem, RNA 
interference (RNAi) has been used as a metabolic engineering tool to knockdown host 
genes responsible for decreasing the yield of recombinant protein.  A novel caspase 
(Tn caspase-1) derived from Trichoplusia ni cells has been identified and 
characterized.  Through modulation of caspase levels via either RNAi or through 
interaction with baculovirus protein p35, the overall level of apoptosis present in cell 
culture has been decreased.  In addition, the use of in vitro RNAi targeted against Tn 
  
caspase-1 has increased the production of recombinant green fluorescent protein.  To 
further study the effect of suppressing Tn caspase-1, a stable cell line producing in 
vivo RNAi was developed, resulting in a nearly 90% decrease in caspase enzymatic 
activity.  This suppression was able to improve culture viability under adverse 
conditions and increase recombinant protein production levels up to two-fold that of 
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Since the introduction of Humulin in 1982, the market for recombinantly 
produced proteins and therapeutics has grown steadily and is predicted to reach over 
$52 billion by the year 2010 (Pavlou and Reichert 2004). As demand increases, so too 
will the need to increase the efficiency of current production systems as well as 
develop new technologies for the production of recombinant proteins. Despite being 
an efficient and convenient method for the production of recombinant protein, one 
drawback associated with the baculovirus expression vector system (BEVS) is that 
host cells fight infection, through the production of proteases and the onset of 
apoptosis.  Baculoviruses have evolved strategies to combat this, but protein 
production is still decreased by proteases and other host cell defenses, including 
apoptosis.  One principal component of this apoptotic machinery is a group of 
proteases known as caspases, which respond to both external as well as internal 
apoptotic signals and carry out the proteolysis that leads to apoptotic cell death.      
To combat this problem, we have identified a novel caspase present in cell 
lines derived from Trichoplusia ni, the cabbage looper, one of the main hosts for 
industrial protein production using the BEVS.  Designated Tn-caspase-1, we have 
shown that it is responsible for the majority of effector caspase activity present in T. 
ni cells, and have demonstrated that its activity can be detected in the latter stages of 
baculovirus infection.  Furthermore, through the suppression of Tn-caspase-1, 




(RNAi), a decade old technology that has quickly become a powerful and widespread 
tool for the sequence specific knockdown of a gene of interest.  Through the use of in 
vitro RNAi, Tn-caspase-1 transcript levels were decreased by 80%, resulting in 
recombinant protein levels more than 2 times that of untreated cells.  Further, in order 
to take advantage of the simplicity and robustness of an in vivo approach, we have 
developed a construct for the expression of in vivo dsRNA and subsequently 
developed the first stable T ni. derived cell line in which it is implemented.  The 
stable cell line selected (designated dsTncasp-2) displays a 90% decrease in caspase 
enzymatic activity during chemically induced apoptosis.  dsTncasp-2 also has 
increased resistance to nutrient starvation and high cell densities as is often seen 
during prolonged suspension culture and demonstrates protein production levels up to 
two-fold that of standard cells.  Overall, this study supports the application of RNAi 
in metabolic engineering for the improvement of recombinant protein production and 
the development of cell lines with desirable production phenotypes.                  
Literature Review 
Baculoviruses  
 Baculoviruses are a diverse family of rod-shaped, occluded double-
stranded DNA viruses with a large, circular genome that ranges from 88 to 200 
kilobase pairs (Ayres et al. 1994; King and Possee 1992).  They are further divided 
into two genera: the Nucleopolyhedrovirus (NPVs) and the Granulovirus (GVs).  In 
general, NPVs produce large occlusion bodies that contain multiple virions while 
GVs produce smaller granular occlusion bodies containing only one virion (Willis et 




multiple nuclear polyhedrosis virus (AcMNPV), which is an NPV that exhibits a 
broad host range across several lepidopteron species, including the cabbage looper 
(Trichoplusia ni) and the fall armyworm (Spodoptera frugiperda) (Granados and 
Federici 1986; Willis et al. 2005).   
The baculovirus replication cycle consists of two phases, which governs the 
transcription of viral genes.  In the first phase, early and late genes are expressed, and 
infected cells produce many non-occluded or budded virus particles (BVs) into the 
medium.  These BVs spread the infection within the insect and in insect cell culture.  
In the second stage of infection, the very late genes are expressed, and the virus 
particles are occluded by the polyhedrin protein to form polyhedra, which protect the 
virus particles from the environment and spread infection between insects.  However, 
production of occluded virus particles is not required to spread infection in cell 
culture (Dalal 2001). 
The two forms of AcMNPV virus particles are shown in Figure 2-1.  The 
DNA is associated with p6.9, a highly basic, arginine-rich protein of 6.5 kilodaltons 
(kDa) and is packaged within a rod-shaped nucleocapsid composed of a 39-kDa 
capsid protein (vp39) and a71-kDa protein (p80) (Miller 1997).  The nucleocapsid is 
then packaged within the lipoprotein envelope to form the virion, which are occluded 
by the polyhedrin protein in the late stages of infection to form polyhedra ranging in 
size from 1-15 μm (King and Possee 1992). 
Baculovirus Expression Vector System (BEVS) 
In order to produce recombinant proteins using an insect cell/baculovirus 




replication.  Usually, genes will be inserted under the control of either the polyhedrin 
or P10 promoter, which are transcribed during the very late time period of infection 
and are two of the strongest promoters known (King and Possee 1992).  However, 
genes can also be inserted under earlier promoters, providing a convenient means of 
detecting infection (Dalal et al. 2005).  Once the recombinant baculovirus particles 
have been constructed, they are introduced into the culture medium, subsequently 
infecting cells and producing the protein of interest.  Genes placed under the control 
of the polyhedrin promoter can generally be detected at approximately 2 days post 
infection (dpi), while detection can be as early as 18 hours post infection (hpi) for 
genes under the control of early promoters.  Cultures are usually harvested at 5-6 dpi, 
when the yield reaches a maximum (Caron et al. 1990).  The insect cell/baculovirus 
expression system has been widely used as a means for producing recombinant 
protein, due to the high yield and correct functionality of the expressed protein 
(Luckow and Summers 1988; Smith et al. 1985).  Yields approaching 50% of total 
cellular protein can be attained in infected cells (Wickham et al. 1992), and 
functionalities including secretion signal recognition (Davis et al. 1992a), assembly of 
oligomeric proteins (Kakker et al. 1999), glycosylation (James et al. 1995), 
phosphorylation (Hericourt et al. 2000), and disulfide bond formation (Hodder et al. 






Figure 1-1. Two common forms of AcMNPV 
The budded and occlusion derived virus forms of AcMNPV are represented. The genes 
that are responsible of each form and those that are common to both forms of the virus 




 In addition to a wide array of promoters and high yield the baculovirus system can 
also accept large amounts of foreign DNA, a task which can be difficult using 
bacterial or yeast systems (Shuler and Kargi 1997).  Scale up is also relatively easy, 
though oxygen depravation can still be a problem at high culture densities (Ikonomou 
et al. 2003).  One way to circumvent this problem is to use the baculovirus in insect 
cell larvae to produce recombinant protein.  Larvae can be fed an inexpensive nutrient 
source and scale linearly, but unfamiliarity with larval systems and easy access to cell 
culture facilities have made this practice relatively rare (Kost et al. 2005).  
Baculovirus vectors can also be used to introduce DNA into mammalian cells.  
Although the exact mechanism of baculovirus entry into mammalian cells has not yet 
been determined, these systems open up a host of new possibilities for the baculovirus 
system (Kost et al. 2005). 
 The baculovirus system has disadvantages as well.  First of all, insect cell 
cultures infected with baculovirus are discontinuous, since the cells eventually die 
after infection.  Also, despite their posttranslational ability, glycosylation in insect 
cells is not the same as it is in mammalian cells, making the production of proteins 
that require complex glycosylation less effective.  However, a great deal of research 
is currently focused on engineering mammalian glycosylation pathways into the 
insect cell/baculovirus system (Betenbaugh et al. 2004; Jarvis 2003; Jarvis et al. 1998; 
Tomiya et al. 2003; Tomiya et al. 2004).  Other disadvantages of the baculovirus 
system include decreased production of secreted or membrane proteins and product 




Improving Yield in the BEVS 
In order to combat low protein yield in the baculovirus system due to 
improper folding, minimal secretion, or degradation by proteases, several strategies 
have been developed.  One technique involves coexpression of chaperone proteins by 
the baculovirus to aid in the folding of recombinant proteins (Ailor and Betenbaugh 
1999).  A number of studies have documented an increase in functional protein as the 
result of coexpressing chaperones such as calnexin (Higgins et al. 2003), calreticulin 
(Fourneau et al. 2004; Zhang et al. 2003), or heat shock proteins (hsps) (Martinez-
Torrecuadrada et al. 2005; Yokoyama et al. 2000).  Examples in both Sf9 (Lenhard 
and Reilander 1997) and T. ni  (Ailor and Betenbaugh 1998; Hsu and Betenbaugh 
1997) cell culture have been reported.  Another technique involves the addition of 
certain DNA enhancer elements to the baculovirus.  Homology regions derived from 
baculovirus inserted upstream of the promoter for the gene of interest have been 
shown to increase luciferase production (Chen et al. 2004; Venkaiah et al. 2004).  In 
addition, enhancer sequences can be constructed from heterologous elements.  
Incorporation of a 21 base pair element derived from a 5’ untranslated leader 
sequence of lobster tropomyosin cDNA and an A-rich sequence found in the 
polyhedrin leader sequence enhanced the expression of tropomyosin and luciferase 
twenty and sevenfold, respectively (Sano et al. 2002).  Protein degradation can also 
be combated by the addition of protease inhibitors to the media (Kato et al. 2003)  or 
through the optimization of harvest time and conditions to minimize protease activity 
(Pham et al. 1999) .    Modification of the baculovirus itself can also be used to 




cathepsin (both of which help liquefy the host during the late stages of infection) 
negative bacmid improved the integrity of both intracellular and secreted recombinant 
protein (Kaba et al. 2004).  Finally, a non-lytic baculovirus was constructed using a 
novel fluorescence resonance energy transfer (FRET) based assay, decreasing the 
percentage of lysed cells from 60% to 7% in Sf21 cells at 5 days post infection (Ho et 
al. 2004).  The authors demonstrated this led to an increased amount of compactly 
folded luciferase with less degradation. 
Apoptosis and Caspases 
Apoptosis, or programmed cell death, was first described by Kerr et al. (1972) 
and has since been recognized as an important component of several biological 
processes including embryonic development, tissue homeostasis, tumorigenesis, and 
viral infection (Walker et al. 1988).  Improper regulation of apoptosis has been 
associated with several diseases, including cancer, autoimmune disorders, and 
neurodegenerative diseases (Thompson 1995).  Apoptosis can occur in a variety of 
cell types and can be triggered by either external or internal signals such as viral 
infection, UV light, or chemicals such as actinomycin D.  During apoptosis, cells 
undergo a number of distinct morphological changes, including the blebbing of the 
plasma membrane, cellular shrinkage, and the formation of apoptotic bodies which 
are generally engulfed by neighboring cells (Kerr et al. 1972).  Thus, the harmful 
contents of the cells are not released into the extracellular space but are instead 
absorbed by neighboring cells, preventing harmful inflammatory responses (Chang 
and Yang 2000).   Apoptosis is morphologically distinct from necrosis, or passive cell 




release of cellular contents (Kim and Park 2003).  Other characteristic biological 
changes associated with apoptosis include DNA fragmentation or laddering due to 
cleavage between nucleosomes, which can be visualized using conventional gel 
electrophoresis and the flipping of the phosphatidylserine from the inner side of the 
plasma membrane to the outside (Chang and Yang 2000).    
 The distinct nature of the apoptotic phenotype is in part due to its highly 
conserved nature as well as its tightly controlled machinery.  The primary component 
in this machinery is a group of proteolytic enzymes known as caspases.  First 
discovered in Cos-7 cells as the interleukin-1 beta converting enzyme (ICE) (Cerretti 
et al. 1992) and first linked to apoptosis with the cloning of the proapoptotic ced-3 in 
Caenorhabditis elegans (Yuan et al. 1993), the term caspase means cysteine specific 
aspase or aspartic protease.  Thus, caspases use a cysteine group as the nucelophilic 
group to cleave the C-terminal peptide of an aspartic acid residue (Alnemri et al. 
1996).   Additional evidence for the involvement of caspases in the apoptotic caspase 
is provided by studies showing that certain synthetic or natural caspase inhibitors, 
such as the cowpox viral serpin CrmA (Tewari et al. 1995) and baculovirus protein 
p35  (Clem et al. 1991)can greatly reduce apoptosis induced by diverse stimuli.  
Further, animals lacking caspases show defects in apoptosis, and caspases are 
responsible for most of the proteolytic cleavage that takes place during apoptosis 
(Chang and Yang 2000).  
 Caspases are translated as latent pro-enzymes that require activation before 
they become active players in the apoptotic process.  As a result, caspases generally 




prodomains (Figure 1-2) and are generally autocatalytic or respond to an apoptotic 
stimuli.  This signal can come from a cell surface receptor, such as the well studied 
CD95/APO-1/Fas receptor (Schmitt et al. 1999), or as through the release of a 
mitrochondrial apoptotic factor such as apoptosis inducing factor (AIF) or 
cytochrome c (Susin et al. 1998).  Effector caspases, such as human caspase-3 or -7, 
have relatively small prodomains and are directly activated by initiator caspases, 
resulting in the cleavage of cellular proteins and apoptotic cell death.  Inflammatory 





Figure 1-2. Mammalian caspases and C. elegans caspase CED-3. 
All mammalian caspases are from human, except mcaspase-11 and mcaspase-12, for which 
human counterparts have not yet been discovered.  Phylogeny is based on similarity between 






RNA based gene silencing was first observed in plants and fungi, and was 
described as post-transcriptional gene silencing (PTGS) or quelling, respectively 
(Corgoni et al. 1996; Jorgensen 2003).  In both cases, attempts to overexpress an 
endogenous gene by introducing transgenic copies backfired and blocked expression 
of the gene.  The first case reported in animals came when Guo and Kemphues (Guo 
and Kemphues 1995) blocked the mRNA expression of the par-1 gene using 
antisense RNA, but noticed that par-1 mRNA itself repressed par-1.  This seemingly 
contradictory observation, subsequently called RNAi (RNAmediated interference) by 
Rocheleau (Rocheleau et al. 1997), laid the foundation for later experiments that 
showed double-stranded RNA (dsRNA) was the trigger of gene silencing (Fire et al. 
1998; Montgomery and Fire 1998).         
Double-stranded RNA causes sequence specific degradation of mRNA to 
which it is homologous, resulting in decreased gene expression, while unrelated 
mRNA transcripts are not affected (Fire et al. 1998; Montgomery and Fire 1998; 
Sharp 1999; Tuschl et al. 1999).  The RNA silencing pathway is triggered by small, 
21-27 nucleotide long “small RNAs,” a term which can include small interfering 
RNAs (siRNAs), repeat-associated small interfering RNAs (rasiRNAs), and micro 
RNAs (miRNAs) (Tomari and Zamore 2005).  siRNAs are produced in vivo by the 
ribonulcease Dicer, which cleaves long dsRNAs into siRNAs (Figure 1-3).  Cellular 
miRNAs are processed by the endonuclease Drosha in the nucleus before being 
exported to the cytoplasm, where they are cut by Dicer to produce mature miRNA 




the same.  Once transcribed or introduced into the cell, these small RNAs affect gene 
expression through a common set of proteins known as RNA silencing effector 
complexes.  These complexes, which include the RNA-induced silencing complex 
(RISC) (Hammond et al. 2000) or the RNA-induced initiation of transcriptional gene 
silencing (RITS) complex (Verdel et al. 2004), bind the small RNAs and direct gene 
silencing through a cascade of reactions.  Once a complementary siRNA duplex has 
loaded onto RISC, Argonaute 2 (AGO2) cleaves the sense (passenger) strand, leaving 
the antisense (guide) strand still incorporated into the now active RISC complex.  
This complex can then recognize and cleave complementary mRNA through the 
catalytic domain of AGO2 (Matranga et al. 2005; Rand et al. 2005).   In the case of 
miRNA, perfectly complementary RNA duplexes are processed in a manner similar 
to siRNA.  Sequences that have imperfect homology use a bypass mechanism that 
unwinds and discards the sense strand, resulting in an active RISC complex that then 
directs translational repression and mRNA degradation (Bagga et al. 2005; Pillai et al. 
2005).  For a more rigorous discussion of the mechanisms of RNA gene silencing, see 






Figure 1-3. Mechanism of RNAi in mammalian cells 
The RNA interference pathway is directed by small RNAs such as small interfering RNAs 
(siRNAs) and microRNAs (miRNAs).  In the siRNA pathway, long double stranded RNA 
(dsRNA) is cleaved into siRNAs by the enzyme Dicer.  These siRNA duplexes then associate 
with Argonaute 2 (AGO2) and the RNA-induced silencing complex (RISC).  When these 
duplexes have complementary sequences, AGO2 cleaves the sense strand, leaving the 
antisense strand still associated with the now active RISC complex.  The active RISC 
complex then binds and cleaves (through the catalytic domain of AGO2) complementary 
mRNA.  miRNAs are first processed in the nucleus by Drosha before exportation to the 
cytoplasm.  While perfectly complementary miRNAs are processed similarly to siRNAs, 
imperfectly complementary strands are processed differently.  Instead of cleavage as with the 
siRNA duplex, the miRNA duplex is unwound and the sense strand is discarded, leaving the 
antisense complex that now functions to either repress or degrade the complementary mRNA 





Applications of RNAi 
Since its initial discovery in 1998 (Fire et al. 1998), RNA interference (RNAi) 
has quickly moved from a tool for single gene loss-of-function studies to a means of 
implementing genetic changes in a specific manner over a wide range of organisms 
and cell types.  In addition to unraveling the mechanisms, origins, and purpose of 
RNAi (Scherer and Rossi 2003; Tomari and Zamore 2005), research has focused on 
improving and creating new delivery methods for both cells and animals (Dann 2007; 
Kumar and Clarke 2007; Mittal 2004), as well as genome wide RNAi screens for 
functional analysis in both mammalian (Aza-Blanc et al. 2003; Cullen and Arndt 
2005; Silva et al. 2004; Sturzl et al. 2008) and drosophila cells (Armknecht et al. 
2005; Boutros et al. 2004).  A recent review examines many of the issues involved in 
genome wide RNAi screens, including cell line selection, screening techniques, and 
infrastructure requirements (Echeverri 2006).  While these screens are a relatively 
new technique for elucidating gene function and interaction, they are rapidly 
becoming powerful and widespread.  
Since  the discovery that RNAi was mediated by short-interfering RNA 
(siRNA) in mammalian cells (Elbashir et al. 2001) and the subsequent demonstration 
of its efficacy in an animal disease model (Song et al. 2003), RNAi has also been 
touted as the next great therapeutic tool for combating a wide range of diseases, 
including cancer (Pai et al. 2006; Pento 2007), neurodegenerative disease (Raoul et 
al. 2006), viral infection (Leonard and Schaffer 2006), and ocular disorders 
(Campochiaro 2006).  Great potential exists, but difficulties remain, including 




quantifying specific and non-specific side effects.  These issues have been addressed 
in greater detail in numerous recent reviews on RNAi as a therapeutic tool  (Aigner 
2006; Bumcrot et al. 2006; Corey 2007; de Fougerolles et al. 2007; Dorsett and 
Tuschl 2004; Dykxhoorn and Lieberman 2005; Dykxhoorn et al. 2006; Gewirtz 2007; 
Grimm and Kay 2007; Novobrantseva et al. 2008; Shankar et al. 2005).  Additional 
applications include antisense applications in bacteria, RNAi in plant biotechnology, 








Antisense in Bacteria 
Therapeutics 
Loss of function and  
High-throughput screening Future Applications 
 
Figure 1-4. RNA interference as a means of altering phenotype. 
RNA constructs are used in research (screening and loss of function), therapeutics 
(Dykxhoorn and Lieberman 2005), metabolic engineering (March and Bentley 2006), plant 
biotechnology, and, in single-stranded form, bacteria. 




RNAi and Metabolic Engineering 
Metabolic engineering typically involves the rational alteration of a host cell’s 
genotype or regulatory network in order to achieve a desired phenotype (Bailey 1991; 
Stephanopoulos and Vallino 1991).   In addition to efficient production of the 
molecule of interest, desirable phenotypes include the ability to survive well in the 
adverse conditions normally experienced by cells overproducing protein, such as 
decreased oxygen and nutrients or increased cellular and oxidative stress (diStefano et 
al. 1995; Rao and Bredesen 2004; Scott et al. 1992).  In general, this involves altering 
the central metabolism, seeking to increase the flux through specific pathways while 
decreasing others.  Traditionally, this has been accomplished either through the 
overexpression of specific targets directly involved in the pathway (Chen et al. 2001; 
Irani et al. 1999) or alteration of the overall protein machinery, such as the expression 
of chaperone proteins (Borth et al. 2005; Davis et al. 2000; Higgins et al. 2003; 
Kitchin and Flickinger 1995; Martinez-Torrecuadrada et al. 2005; Yokoyama et al. 
2000) or transcriptional factors involved in the secretory pathway (Tigges and 
Fussenegger 2006).  A similar approach can be taken using RNAi and other antisense 
technologies; instead of overexpressing desirable genes, potentially deleterious genes 
are silenced.         
RNAi initially found limited use in metabolic engineering, however, perhaps 
due to its transient nature, relatively inefficient delivery methods, and the more 
typical metabolic engineering objective functions that are based on permanent 




based on antisense RNA have appeared, targeting apoptosis, the cell growth cycle, 
and glycosylation.   
Since apoptosis (programmed cell death) can account for up to 80% of cell 
death in bioreactors and lead to decreased product yield and quality (Goswami et al. 
1999; Mastrangelo and Betenbaugh 1998; Mercille and Massie 1994), anti-apoptosis 
engineering has become an important area of metabolic engineering.  This strategy 
has also been implemented using RNAi.  Examples include RNAi against proteases in 
CHO (Lai et al. 2004; Wong et al. 2006b) and Sf9 cells (Lin et al. 2007) and 
produced by recombinant baculovirus (Kim et al. 2007).  In each of these examples, 
the yield of recombinant protein was enhanced as a result of the downregulation of a 
target protease.   
A more global approach involves altering the cell growth cycle using RNAi.  
An optimal production cycle is generally biphasic.  The cells first grow quickly to a 
high density before transitioning to a production phase characterized by low growth 
and high productivity (Fussenegger 2001; Gammell et al. 2007).  Achieving this 
regime is relatively straightforward in bacterial systems, but can be more problematic 
in eukaryotic cell culture since their state is influenced by the cell cycle.  Studies have 
investigated the relationship between the cell cycle and heterologous protein 
expression and some attempts have been made to optimize product synthesis by using 
a cycle-specific promoter (Banik et al. 1997; Banik et al. 1996), or controlling the cell 
cycle itself (Ibarra et al. 2003; Kim et al. 2000; Simpson et al. 1999; Watanabe et al. 
2002).  RNAi has again proven a viable alternative, as it has been used to increase 




of cell growth controllers (March and Bentley 2006; March and Bentley 2007) and in 
HEK 293 cell through the downregulation of transcriptional regulators (Hacker et al. 
2004). 
 A final area of metabolic engineering in which RNAi has played a role is 
glycosylation.  Engineering specific glycosylation patterns can increase the potency 
and stability of therapeutic proteins while at the same time decreasing their 
immunogenic effects (Butler 2006; Jenkins 2007; Kuystermans et al. 2007), and has 
been the subject of study in several systems including mammalian (Butler 2006), 
insect (Tomiya et al. 2004), and yeast (Wildt and Gerngross 2005).  Several specific 
examples of using RNAi to fine tune glycosylation patterns include increasing the 
antibody-dependent cellular cytotoxicity of antibodies produced in CHO cells through 
the reduction of a 1,6 fucosyltransferase (FUT8) (Mori et al. 2004) , GDP mannose 
4,6 dehydrogenase (GMP) (Kanda et al. 2007), or both FUT8 and GMP (Imai-
Nishiya et al. 2007), as well as improving product quality by reducing sialidase 
activity in CHO cells (Ngantung et al. 2006).   
 As the amount of genomic and metabolomic data increases, additional RNAi-
based metabolic engineering targets will surely be identified.  Some such screens are 
already underway (Gammell et al. 2007; Lee et al. 2007; Wong et al. 2006a), and as 








RNAi and Baculovirus 
 
Several instances of using RNAi in conjunction with baculovirus have been 
reported.  One of the first studies used antisense RNA made by the baculovirus under 
the control of the p10 promoter to decrease juvenile hormone esterase in the tobacco 
budworm Heliothis virescens and affect its development (Hajos et al. 1999).  Several 
more recent studies have used dsRNA against essential viral genes made either in 
vitro (Valdes et al. 2003) or in vivo (Isobe et al. 2004) to confer baculovirus 
resistance to both cells and larvae, or to study the mechanics of baculovirus infection 
(Flores-Jasso et al. 2004; Means et al. 2003).  RNAi against genes encoded by the 
baculovirus has proven effective (Agrawal et al. 2004; Kramer and Bentley 2003), but 
the silencing of host genes by RNAi during baculovirus has not been examined 
thoroughly.  Some preliminary work has shown that RNAi can be used to increase 
protein production in the baculovirus system (Kim et al. 2007; Kramer 2002), laying 












Previous studies in by both the Bentley lab and others have demonstrated the efficacy 
of RNAi as a means of improving recombinant protein production.  The objectives of 
this project focus around the application of RNAi to improve protein production in 
the baculovirus expression system and are given below:  
 
Objective 1: Identify and characterize novel gene targets, such as cell death genes and 
proteases, which could be responsible for decreasing yield in the baculovirus 
expression system.   
 
Objective 2: Evaluate potential targets using in vitro synthesized dsRNA.  Both the 
level of suppression and the effect on recombinant protein production will be 
measured.   
 
Objective 3: Select the most promising targets for implementation with in vivo 
dsRNA by developing a cell line that expresses a dsRNA hairpin construct.  Evaluate 








Chapter 2 : Characterization and Analysis of Trichoplusia ni 
Caspase-1 Through Overexpression and RNAi Mediated 
Silencing 
Abstract 
In both mammals and invertebrates, caspases play a critical role in apoptosis.  
Although Lepidopteron caspases have been widely studied in Spodoptera frugiperda 
cells, this is not the case for Trichoplusia ni cells, despite their widespread use for the 
production of recombinant protein and differences in baculovirus infectivity between 
the two species. We have cloned, expressed, purified and characterized Tn-caspase-1 
in several situations: in its overexpression, in silencing via RNA interference (RNAi), 
during baculovirus infection, and in interactions with baculovirus protein p35.  
Overexpression can transiently increase caspase activity in T. ni (High Five™) cells, 
while silencing results in a greater than 6-fold decrease.  The reduction in caspase 
activity resulted in a reduction in the level of apoptosis, demonstrating the ability to 
affect apoptosis by modulating Tn-caspase-1. During baculovirus infection, caspase 
activity remains low until approximately 5 days post infection, at which point it 
increases dramatically, though not in those cells treated with dsRNA.  Our results 
demonstrate that Tn-caspase-1 is the principal effector caspase present in High Five 
cells, and that it is inhibited by baculovirus protein p35.  Finally, our results indicate 
differences between RNAi and p35 as effector molecules for modulating caspase 





Although apoptosis was first described over thirty years ago (Kerr et al. 1972), 
it remains an active area of research in many fields as a result of its role in 
development,  homeostasis, and host defense (Steller 1995; White 1996), and because 
a multitude of questions remain to be answered.  Deficiency in apoptosis has been 
linked to human diseases including cancer, certain autoimmune disorders, and 
neurodegenerative diseases (Peter et al. 1997; Thompson 1995).  Well conserved 
throughout higher organisms, a central component of the machinery of apoptosis is a 
family of aspartate-specific cysteine proteases known as caspases (Chang and Yang 
2000; Earnshaw et al. 1999; Salvesen and Dixit 1997).  
 First described in mammalian systems (Cerretti et al. 1992; Thornberry et al. 
1992) and shortly thereafter in Caenorhabditis elegans (Lazebnik et al. 1994; Yuan et 
al. 1993), caspases are generally divided into three groups.  Inflammatory caspases, 
which are involved in cytokine activation, comprise the first group and include 
human caspases-1, -4, -5, -11, -12, -13, and -14 (Chang and Yang 2000).  The second 
group, initiator caspases, includes caspase-2, -8 and -9, and the third group, effector 
caspases, includes caspase-3 and -7 (Chang and Yang 2000).  Although the exact 
mechanism is not fully understood, initiator caspases respond to a variety of signals 
that result in the cleavage of their long N-terminal prodomain, which in turn results in 
the cleavage and subsequent activation of effector caspases, which have relatively 
short prodomains.  These activated effector caspases cleave cellular proteins, 




 In invertebrates, caspases also play a important role in apoptosis (Bergmann et 
al. 1998; Clem 2005; Clem et al. 1996).  Drosophila melanogaster has been the most 
studied insect system of apoptosis, with seven caspases identified based on sequence 
similarity and biochemical activity (Vernooy et al. 2000).  Drosophila Dronc, Dcp-
2/Dredd, and Strica have long prodomains, similar to initiatior caspases, while Drice, 
Dcp-1, Damm and Decay have short prodomains, similar to effector caspases (Muro 
et al. 2004).  Another well studied insect system includes the Sf9 and Sf21 cell lines, 
both of which are derived from the lepidopteron species Spodoptera frugiperda.  
These lines are particularly suited for studies in apoptosis due to their susceptibility to 
a wide array of apoptotic stimuli, including UV radiation, baculovirus infection, 
chemical agents such as actinomycin D, and overexpression of Drosophila death 
genes such as reaper or hid (Clem et al. 1991; Manji and Friesen 2001; Vucic et al. 
1997b). 
 Sf-caspase-1 is the principal effector caspase in Sf cell lines (Ahmad et al. 
1997; LaCount et al. 2000).  Its activation is believed to follow a two-step process, in 
which an unidentified initiator caspase (Sf-caspase X) cleaves pro-Sf-caspase-1 D195, 
producing the small subunit p12, and an intermediate fragment, p25.  The second step 
cleaves the small prodomain from the p25 fragment at D28, resulting in the formation 
of P6 and the large subunit p19 (Manji and Friesen 2001).  A recent study has 
identified an alternative activation pathway, in which pro-Sf-caspase-1 is first cleaved 
at D28 and then D195, resulting in active Sf-caspase-1 (Liu and Chejanovsky 2006).   
As a result of evidence suggesting that apoptosis is used by the cells as an antiviral 




characterized with respect to Sf-caspase-1 activation.  Inhibitors of apoptosis (IAPs), 
including Op-IAP from the baculovirus Orgyia pseudotsugata nucleopolyhedrovirus 
(OpNPV), block apoptosis upstream of Sf-caspase-1, perhaps by preventing the 
activation of Sf-caspase-X or other pro-apoptotic proteins (Birnbaum et al. 1994; 
Vucic et al. 1997a; Zoog et al. 2002).  P35, a caspase inhibitor from the baculovirus 
Autographa californica multiple nucleopolyhedrovirus (AcMNPV), blocks the 
cleavage of the prodomain (Ahmad et al. 1997; Bertin et al. 1996; LaCount et al. 
2000; Manji et al. 1997), while P49 from Spodoptera littoralis nucleopolyhedrovirus 
(SlNPV) blocks cleavage into the large and small subunits (Zoog et al. 2002).  
Because of their ability to inhibit apoptosis, IAP and p35 containing vectors have 
been successfully employed in recombinant protein expression systems to extend 
production times and increase product yield (Jabbour and Hawkins 2004; Lin et al. 
2001; Sauerwald et al. 2003; Vives et al. 2003).    
 While Sf-derived host cells are widely used in the Baculovirus Expression 
Vector System (BEVS) for the production of recombinant protein (Cha et al. 1999c; 
Cruz et al. 1999);  Trichoplusia ni cells (Ailor et al. 2000; Davis and Wood 1995; 
Jarvis 2003) and larvae (Cha et al. 1999a; Cha et al. 1997; Kramer and Bentley 2003; 
Pham et al. 1999) have been reported to have superior productivity (Davis et al. 
1992b; Wickham et al. 1992; Wickham and Nemerow 1993)  and yet no reports have 
appeared on caspases in T. ni.  Indeed, only two reports have appeared concerning 
caspases in lepidopteron cell lines other than Sf (Liu et al. 2005; Pei et al. 2002).  
Additionally,  differences in infectivity seen between different species of lepidopteron 




Haas-Stapleton et al. 2003; Hershberger et al. 1992) and the effects of protease 
activity on recombinant protein yield (Cruz et al. 1999; Naggie and Bentley 1998; 
Pham et al. 1999) on have stimulated our interest in T. ni caspases. 
 In this study, we have identified, cloned, expressed and purified Tn-caspase-1 
based upon the existing Genbank sequence for Tn-caspase (AAO17788).  Subsequent 
experimental objectives included 1.) Modulation of the caspase activity in T. ni cells 
through overexpression and knockdown of Tn-caspase-1 via double-stranded RNA 
(dsRNA), 2.) Determination of caspase activity during baculovirus infection, 3.) 
Evaluation of baculovirus protein p35 as an inhibitor of caspase activity, and 4.) 
Characterization of apoptosis with respect to caspase activity.  Our results 
demonstrate that overexpression of Tn-caspase-1 can transiently increase caspase 
activity, while silencing of Tn-caspase-1 results in a greater than 6-fold decrease in 
caspase activity, which also translates into a reduction in overall apoptosis.  dsRNA 
can also reduce the high levels of caspase activity seen during the latter stages of  
baculovirus infection.  Finally, heterologously expressed baculovirus protein p35 can 
also inhibit caspase activity and apoptosis, although not as effectively as RNAi under 





Materials and Methods 
Cell culture, transfection, and infection  
 Trichoplusia ni BTI-TN-5B1-4 (High FiveTM, Invitrogen) cells were cultivated in 
EX-CELLTM-405 media (SAFC Biosciences) at 27°C. Unless otherwise noted, cells were 
initially plated on 24 well plates at a density of 3×105 cells/mL and transfected the following 
day using Cellfectin® (Invitrogen) according to the manufacturer’s procedure.  Briefly, 
culture media was aspirated from the wells and the transfection mixture was added for a 4 
hour incubation period.   Subsequently, the transfection mixture was removed; cells were 
washed with media, and then returned to the incubator in fresh media.  In the case of infection 
with baculovirus, cells were infected 24 hours post transfection as previously described with 
a Multiplicity of Infection (MOI) of 2 (Eun Jeong Kim 2007). 
 
Baculovirus  
A recombinant Autographa californica multiple nucleopolyhedrovirus (AcMNPV) 
that expresses GFPuv under the control of the polyhedron promoter was created previosuly 
(Cha et al. 1999a; Cha et al. 1999b; Cha et al. 1999c). The baculovirus was propagated in 
High FiveTM cells (Invitrogen), and Spodoptera frugiperda (Sf-9) cells (Invitrogen) following 
the general protocols outlined in O’Reilly et al. (O'Reilly et al. 1992).  The titer of 
baculovirus was determined by the endpoint dilution method (O'Reilly et al. 1992).  
 
RNA Isolation, cDNA cloning, and In vitro dsRNA synthesis 
Total RNA was extracted using RNAqueous (Ambion) according to the 




minutes, and lysed using the provided lysis/binding buffer.  Following the RNA isolation, 
samples were subjected to a DNAse digest for 30 minutes per the manufacturer’s instructions 
in order to remove any contaminating DNA.  First strand templates of each target gene were 
synthesized from 500 ng of total mRNA using oligo-dT primers and Superscript RT III 
(Invitrogen). 700-900 base-pair regions of first strand DNA templates were PCR amplified by 
AccuPrime™ Taq DNA Polymerase High Fidelity (Invitrogen) using gene-specific primers 
for T. ni-caspase (5’-CGA TCA AAA TGC TGG ACG GTG-3’;5’-AAG TCT GCA TGC 
ACA GGA AT 3’). T7 sequences (TAA TAC GAC TCA CTA TAG GGA) were added in a 
subsequent PCR step, resulting in T7 templates. To make the dsRNA, sense and anti-sense 
RNA was transcribed from T7 templates using the Megascript™ kit (Ambion) following the 
manufacturer’s instructions. The single-stranded RNA (ssRNA) synthesized was extracted 
using phenol/chloroform, resuspended in nuclease free water, and then incubated at 65° C for 
10 min before cooling to room temperature, annealing the two strands to form dsRNA. 
dsRNA was checked for size and integrity using agarose gel electrophoresis and then diluted 
to a concentration of 3 μg/μL.  dsRNA was transfected into cells at a concentration of 
15ug/mL.   
Differential display 
 For determining relative transcript levels, RNA was extracted from High Five cells 
using an RNAqueous kit (Ambion) as described above.  RNA concentration was determined 
by measuring the absorbance of a diluted sample at the 260 nanometer wavelength in a UV 
spectrophotometer (Beckman).  500 ng of total RNA was subject to reverse transcription 
using oligodT primers to obtain the first-strand cDNA template.  The cDNA template was 
subject to PCR with sequence-specific primers: T. ni-caspsae  (5’-TTC ATT CGA TCC CTG 
GAT AGC-3'; 5’ TAG TAT CCA GGC ACG GTG GAG 3’).  PCR products were run on a 




light.  Primers against a 300 bp section of actin (5'-GAT ATG GAG AAG ATC TGG CA 3’; 
5’-GCG TAG CCC TCG TAG ATG-3’) were used to PCR amplify a loading control from 
the reverse transcript.  Photographs of agarose gels under UV light were taken with an 
AlphaImager® HP (Alpha Innotech) and analyzed for band intensity using AlphaEaseFCTM 
(Alpha Innotech).  
 
Plasmid Construction 
 pIB-TnCasp was constructed by PCR amplification of T. ni cDNA using the 
following gene specific primers for tn-caspase-1 (5’-TAA GCC ACC ATG CTG GAC GGT 
GAA TCC CAG-3; 5’ GCG CTT TTT ACC AAA TAC AAG TAG ACG 3’).  The forward 
primer included a Kozak consensus sequence (Kozak 1987; Kozak 1990; Kozak 1991), and 
the reverse primer included the native stop codon.  This PCR fragment was then TOPO® 
cloned into pIB/V5-His-TOPO® (Invitrogen).  This plasmid uses the OpIE2 promoter 
(Theilmann and Stewart 1992) for constitutive expression of the gene of interest in insect 
cells.    pIB-TnCasp-HIS was constructed using the same forward primer, but a reverse 
primer that omitted the native stop codon (5’ GCG CTT TTT ACC AAA TAC AAG TAG 
ACG), allowing for the translation of the poly-histidine tag included in the pIB/V5-His-
TOPO® backbone to aid in purification.  pIB-p35 was constructed through the PCR 
amplification of baculovirus infected T. ni cDNA using the following gene specific primers 
for Autographa californica multiple nucleopolyhedrovirus p35 (gi 9627742:116492-117391) 
(5’-TAA GCC ACC ATG TGT GTA ATT TTT CCG GTA -3’; 5’ GGG GCT GCT TAT 
TTA ATT GTG TTT AAT AT  3’).  This PCR fragment was then TOPO cloned into pIB/V5-
His-TOPO® to produce pIB-p35.  DNA sequencing was performed at the DNA core facility 
of the Center of Biosystems Research (University of Maryland Biotechnology Institute).  All 






 In order to isolate Tn-caspase-1-HIS, crude cell lysates were purified using TALON® 
Metal Affinity Resin (ClonTech) per the manufacturer’s instructions.  Briefly, 250uL of 
lysate was bound to 60uL resin and washed several times with 1mL Equilibration/Wash 
buffer (50 mM Sodium Phosphate, 300 mM NaCl, pH 7.5).  Purified protein was then eluted 
in two steps using 100 uL Elution buffer (50 mM Sodium Phosphate, 300 mM NaCl, 150 mM 
Imidazole, pH 7.0) in each step and stored for later analysis.     
Immunoblot Analysis 
 Cell lysates or purified protein fractions were subjected to SDS polyacrylamide gel 
electrophoresis at 160V for ~1 hour using the BioRad Mini Protean 3 system and then 
transferred to a nitrocellulose membrane using a BioRad Trans-Blot semi-dry transfer cell.  
Tn-caspase-1 was detected using a 1:1000 dilution of α-SfCasp-1 (LaCount et al. 2000), 
kindly provided by P.D. Friesen (University of Wisconsin-Madison), and a 1:2000 dilution of 
goat anti-rabbit HRP (GE Healthcare), which was then developed using the SuperSignal® 
West Pico chemi-luminescence kit (Pierce) and visualized using a Bio-Rad Chemidoc XRS.  
Protein size was approximated using the Magic Mark™ XP Western Protein Standard 
(Invitrogen).           
  
Assay of Caspase activity  
           After various experimental treatments, including actinomycin D (see Results 
and Discussion), cells were collected and washed with PBS (pH 7.5). The cells were 




incubated on ice for 30 min.  Cell debris was removed by centrifugation and 
supernatants were stored for further use or assayed directly. The tetrapeptide N-
acetyl-Asp.Glu.Val.Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) was used as 
the substrate. Cell lysates were added to the reaction buffer (from caspase 3 assay kit, 
BD Bioscience) with Ac-DEVD-AMC and incubated for several hours at 37°C. The 
release of AMC was measured using a Spectramax M5 Plate Reader (Molecular 
Devices) (excitation λ380nm, emission λ440nm).  Caspase activity is defined as the slope 
of the plot of Fluorescence vs. Incubation time.   
 
TUNEL Staining 
 Apoptosis was visualized using the In Situ Cell Death Detection Kit, 
Fluorescein (Roche Applied Sciences) according to the manufacturer’s instructions.  
After various treatments, including actinomycin D, cells were washed with PBS prior 
to fixation with a 4% paraformaldehyde solution for 1 hour at room temperature.  The 
cells were then washed once with PBS and permeabilized using a solution of 0.1% 
Triton-X in 0.1% Sodium Citrate for 5 minutes on ice.  Subsequently, cells were 
washed twice with PBS before incubation with the TUNEL reaction mixture for 1 
hour at 37 °C.  Cells were again washed twice with PBS before visualization under a 
fluorescent microscope or analysis via flow cytometry.  Fluorescent images were 
taken using a Zeiss Axiovert 40 CFL.  Flow cytometry was conducted on a 
FACSCalibur (BD Bioscience, NJ, USA).  Fluorescence intensity was determined for 




DNA Laddering Assay 
Cells were seeded in 24 well plates at a density of 300,000 cells/mL (150,000 
cells/well).  The following day, actinomycin D was added at various concentrations 
(see supplemental Figure 2a) for a period of 24 hours.  Cells were then sloughed from 
well plates and spun at 500 x g for 5 minutes.  Cell pellets were then resuspended in 
400 uL lysis buffer (Ambion, RNAquoes kit) and extracted using an equal volume of 
phenol/chloroform.  An equal volume of isopropanol was added to the extracted 
aqueous fraction which was then stored overnight at -80 ˚C.  The following day, 
samples were spun for 10 minutes at 14,000 x g (4 °C) to pellet the DNA/RNA.  The 
pellets were then washed twice with 100% ethanol before resuspenion in 100 uL 
nuclease free water.  The samples were then incubated with 1 uL RNAse H 
(Invitrogen) for 45 minutes at 37 °C to digest any remaining RNA.  Samples were 
quantified using UV spectrometry and 2 ug of each sample was run on a 1.5% 
agarose gel.  Bands were visualized using ethidium bromide and UV light.   
Viable cell count 
Cells were seeded in 60 mm2 plates at a concentration of 250,000 cells/mL 
and exposed to 2 ug/mL actinomycin D 24 hours post seeding.  Counts were made 
using Trypan Blue exclusion at various timepoints (see supplemental Figure 2b).      
Labeling using Vybrant® Apoptosis Assay Kit #4 
Cells were seeded in 24 well plates at a density of 300,000 cells/mL (150,000 
cells/well).  The following day, actinomycin D was added at a concentration of 2 




Assay Kit #4 (Invitrogen, CAT #V13243) according to the manufacturer’s 
instructions.  The labeling solution was then prepared using 1 uL of each labeling 
component (YO-PRO®-1 and Propidium Iodide) per 1 mL of PBS buffer (pH 7.4).  
Following incubation with actinomycin D, media was aspirated from each well and 
cells were washed once with 500 uL PBS buffer before addition of 500 uL labeling 
solution to each well.  Cells were incubated with the labeling solution on ice for 30 





cDNA cloning and sequence analysis 
 
In order to isolate tn-caspase-1, total RNA was extracted from High Five cells 
and a cDNA library was constructed using RT-PCR.  Using the existing Genbank 
sequence for T. ni caspase (AAO17788) as a guide, gene specific primers that omitted 
the native stop codon were used to amplify tn-caspase-1, which was subsequently 
cloned into pIB/V5-His-TOPO® (Invitrogen) to produce pIB-TnCasp-HIS.  Upon the 
sequencing of positive transformants, it was apparent that discrepancies existed 
between the Genbank (gb) sequence and all the clones sequenced for this study.  A 
reduced ClustalW sequence alignment of the protein sequence from this study, 
subsequently denoted Tn-caspase-1, (done so because it is the first caspase described 
in T. ni and not because it is necessarily the T. ni analog to Sf caspase-1), 
gb|AAO17788, and closely related caspases is shown in Figure 2-1.  Black boxes 
indicate identical amino acids, gray boxes indicate related amino acids, white boxes 
indicate a difference in amino acids, and dashes indicate a blank position.  Tn-
caspase-1 is most closely related to the three Lepidopteron caspases, Sl-caspase 1 (gb 
AAO16241, 88% sequence identity), Sf-caspase 1 (gb AAC47442, 85%) and Bm-
Caspase (gb NP_001037050, 79%).  Tn-caspase-1 also shares similarity with 
Caspase-7 from both mouse (gb  NP_031637, 41%) and human (gb AAH15799, 
41%).    
The cleavage domains of Sf-caspase 1 (LaCount et al. 2000) are indicated by 






Figure 2-1. ClustalW multiple sequence alignment of Tn-caspase-1 and related caspases 
Default alignment values were used (ClustalW 1.82) and shading was performed using 
BOXSHADE. Black boxes indicate identical amino acids, gray boxes indicate related amino 
acids, white boxes indicate a difference in amino acids, and dashes indicate a blank position. 
The GenbankTM accession numbers of the protein sequences used for the alignment are: 
AAO16241 (Sl-Caspase-1), AAC47442 (Sf-Caspase-1), NP_001037050 (Bm-Caspase-1), 
NP_031637 (Mm-Caspase-7), and AAH15799 (Hs-Caspase-7).  Arrows indicate differences 
in the protein sequence of Tn-caspase-1 between AAO17788 and the results of this study, 
while the boxes above the sequence represent the binding domains of Sf-caspase-1 (LaCount 




representing the cleavage site.  Tn-caspase-1 has identical amino acids at each of 
these cleavage sites, indicating that they might also serve as cleavage sites in Tn-
caspase-1.  The sequence from this study differs from gb|AAO17788 at two amino 
acid positions (indicated by arrows), 94 and 181.  In gb|AAO17788, both amino acids 
94 and 181 are serine; however, in Tn-caspase-1, as well as all the other caspases 
analyzed, these amino acids are leucine.  The conserved nature of these amino acids 
throughout all caspases suggests that the published Genbank sequence is incorrect.  
Since these caspases are effector caspases with relatively short prodomains (Chang 
and Yang 2000), it seems likely that Tn-caspase-1 is as well.       
Protein expression, purification and detection 
  In order to isolate Tn-caspase-1, cells were transfected with pIB-TnCasp-HIS, 
which produces a modified Tn-caspase-1 with a polyhistidine tag for purification 
using a metal affinity resin.  Two sets of cells were transfected: one was exposed to 
actinomycin-D, a chemical apoptosis inducer, at 2 days post-transfection (24 hours at 
2μg/mL), while the other remained untreated.  Both crude lysates and purified protein 
fractions from untreated and actinomycin D exposed cells were subjected to SDS-
PAGE and Western Blot analysis.  Tn-caspase-1 was visualized using α-SfCasp-1 as 
the primary antibody and Anti-Rabbit HRP as the secondary antibody.  Results are 
presented in Figure 2-2.  Crude lysates from untreated cells show a strong band at ~35 
kDa which presumably represents uncleaved Tn-caspase-1, and a faint band at ~23 
kDa which represents a cleavage product.  Crude lysates from cells exposed to 
actinomycin D have a much stronger band at ~23, and a band at ~ 19 kDa, which 




shows that chemically induced apoptosis results in the cleavage of Tn-caspase-1.  The 
purified fractions, while fainter, show similar bands in both untreated and 







Figure 2-2. Tn-Caspase-1 Western Blot.  
Western blot of native and HIS-purified Tn-caspase-1, in the presence and absence of 
actinomycin-D.  Lanes are as follows: M. Protein Standard, 1. Crude lysate from untreated 
High FiveTM Cells, 2., Crude lysate from cells treated with Actinomycin-D (24 hours at 2 
μg/mL), 3. HIS-purified protein fraction from untreated cells, 4. HIS-purified protein fraction 
from cells treated with Actinomycin-D (24 hours at 2 μg/mL). The dashed line represents the 





Tn-caspase-1 overexpression and RNAi silencing – In vivo protein activity 
In order to determine the nature of Tn-caspase-1 in vivo, overexpression and 
RNAi silencing experiments were conducted by transfecting High Five cells with 
pIB-TnCasp (2 ug/mL) and dsRNA synthesized against tn-caspase-1 (15 ug/mL), 
respectively.  Control cells were transfected with pIB-CAT (2ug/mL, Invitrogen).   
Cells were seeded in 24 well plates and harvested 3 days post transfection.  Initial 
experiments showed no increase in caspase activity as a result of overexpression (data 
not shown), suggesting that an apoptotic stimuli was required to fully activate Tn-
caspase-1.  This behavior is consistent with previous studies involving overexpression 
of Sf-Caspase-1 (Ahmad et al. 1997; LaCount et al. 2000).  In subsequent 
experiments, a subset of cells was treated with actinomycin D, a chemical inducer of 
apoptosis.  Although it was previously reported (Clem and Miller 1994) that a 
different T. ni derived cell line (TN-368) was resistant to actinomycin D induced 
apoptosis, this was not the case with High Five™ cells, as we observed both DNA 
laddering and cell death upon exposure to actinomycin D (see appendix, Figures 5-1 
and 5-2).  Additional evidence for the induction of apoptosis upon exposure to 
actinomycin D is given in appendix Figure 5-3, which shows labeling results using 
the Invitrogen's Vybrant® Apoptosis Assay Kit #4 (CAT V13243), which labels 
necrotic cells red using Propidium Iodide and apoptotic cells green using YO-PRO®-
1.  While dead cells are seen in both groups (with a greater number of dead cells in 
the actonimycin D treated cells), a much greater number of green (apoptotic) cells are 




for 9 or 24 hours at a concentration of 2 μg/mL.  Actinomycin D was added in a 
manner that allowed the cells to be harvested at 72 hours post transfection.  Thus, in 
the case of 24 hours exposure, actinomycin D was added at 48 hours post 
transfection, while in the case of 9 hours exposure, actinomycin D was added 63 
hours post transfection.  Results are presented in Figure 2-3.  As determined by RT-
PCR and visualized using differential display, knockdown of tn-caspase-1 was quite 
effective in both the presence and absence of actinomycin D (Figure 2-3).  However, 
no significant difference in transcript levels was seen between cells transfected with 














Figure 2-3. RT-PCR results for overexpression and RNAi silencing of Tn-caspase-1. 
Cells were transfected with either pIB-CAT (control), pIB-TnCasp (caspase overexpression), 
or dsRNA against tn-caspase-1 (silencing).  Transcript levels of both Tn-caspase-1 and actin 
measured at 3 days post transfection, in the presence or absence of actinomycin D (9 hours at 





To investigate the effects of knockdown and overexpression at the protein level, 
Western Blot analsysis was performed on crude lysates from cells transfected with 
pIB-CAT, pIB-TnCasp, and dsRNA targeting Tn-caspase-1 (in the absence of 
actinomycin D).  Results are shown in Figure 2-4a.  While the Tn-caspase-1 level is 
similar in cells transfected with pIB-CAT and pIB-TnCasp, there is a marked 
decrease in those cells transfected with dsRNA.   The caspase activity of cell lysates 
was measured using Ac-DEVD-AMC, which acts as a substrate for Human Caspase 
3/7 and emits fluorescence upon cleavage.  In the absence of actinomycin D, there 
was no significant difference between the caspase activity of cells transfected with 
pIB-CAT versus pIB-TnCasp (Figure 2-4b).  However, cells transfected with dsRNA 
against Tn-caspase-1 showed a significant (p<0.05) reduction in caspase activity.  
Upon exposure to actinomycin D for 9h, cells transfected with pIB-CAT had a nearly 
7-fold increase in caspase activity, while cells transfected with pIB-TnCasp had an 
even larger increase at greater than 12-fold compared to pIB-CAT in the absence of 
actinomycin D.  The caspase activity of cells transfected with dsRNA remained low 
even in the presence of actinomycin D, indicating that the silencing of Tn-caspase-1 
was effective at the protein level.  Cells exposed to actinomycin D for 24 hours 
showed no significant difference between those transfected with pIB-CAT and pIB-
TnCasp, which had caspase activities of roughly 14 and 13 times that of the 
unexposed control, respectively.  The caspase activity of cells treated with dsRNA 
and exposed to actinomycin D for 22h did increase as compared to the 9h exposure, 
but remained far lower than either pIB-CAT or pIB-TnCasp transfected cells, at just 
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Figure 2-4. Western Blot, and Caspase activity results for overexpression and RNAi 
silencing of Tn-caspase-1.  
A, Western blot of Tn-caspase-1, all lysates in the absence of Actinomycin D.  Lanes are as 
follows: M. Protein Standard, 1. Crude lysate from cells transfected with pIB-CAT, 2., Crude 
lysate from cells transfected with pIB-TnCasp, 3. Crude lysate from cells transfected with 
dsRNA against tn-caspase-1.  B, caspase activity of cell lysates measured at 3 days post 
transfection, in the presence or absence of actinomycin D (9 or 24 hours at 2mg/mL).  * - 
indicates a statistically significant (p<0.05) difference between the treated and control values 






as a result of dsRNA treatment at all conditions, including cells not exposed to 
actinomycin D, indicates that tn-caspase-1 is responsible for the majority of the 
caspase 3/7 activity in High Five cells, and is likely the primary effector caspase in 
this cell line.                                 
Tn-caspase-1 overexpression and RNAi silencing – Effects on apoptosis  
 Photomicrographs were taken of both control and treated cells in the presence 
and absence of actinomycin D in order to examine cellular morphology.  In the 
absence of actinomycin D (Figure 2-5), all treatment groups (CAT, TnCasp, dsRNA) 
display normal morphology.  However, upon exposure to actinomycin D (24 hours), 
both pIB-CAT and pIB-TnCasp transfected cells present apoptotic symptoms, 
including degradation of the cell membrane and the formation of apoptotic bodies, 
while cells treated with dsRNA against Tn-caspase-1 present a far more normal 
morphology with only minor apoptotic characteristics.  Fluorescein based TUNEL 
staining was also used to determine the effect of overexpressoin and knockdown of 
tn-caspase-1 on the overall level of apoptosis in transfected cells.  Terminal 
transferase catalyzes the addition of fluorescein-dUTP to single and double-stranded 
DNA breaks that occur as cells undergo apoptosis.  As a result, apoptotic cells appear 
green when visualized with fluorescent microscopy or analyzed via flow cytometry.  
Labeling results are presented in Figure 2-6.  Under all three conditions, untreated 
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Figure 2-5. Photomicrographs for overexpression and RNAi silencing of Tn-caspase-1. 
Cells were transfected with either pIB-CAT (control), pIB-TnCasp (caspase overexpression), 
or dsRNA against Tn-caspase-1 (knockdown).  A, photomicrographs (100x magnification) of 
either untreated cells or cells exposed to actinomycin D (24 hours at 2ug/mL) taken 72 hours 
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Figure 2-6. Flourescent TUNEL staining for overexpression and RNAi silencing of Tn-
caspase-1. 
Fluorescent micrographs (100x magnification) of either untreated cells or cells exposed to 
actinomycin D at each condition visualized using Fluorsecin based TUNEL staining.  Green 









actinomycin D for 24h, both pIB-CAT and pIB-TnCasp transfected cells showed 
strong fluorescence, while dsRNA transfected cells exhibited noticeably less 
fluorescence, though still greater than untreated cells.  This fluorescence was 
quantified using flow cytometry, the results of which are presented in Figure 2-7.  
Populations were first gated based on forward and side scatter to ensure only cells 
were counted.  Then the cells were gated on fluorescence such that 5% of untreated 
control cells were considered positive for apoptosis.  Representative histograms, 
labeled with the percentage of cells considered to be positive for apoptosis, are shown 
in Figure 3c.  Consistent with the caspase activity data, both pIB-CAT and pIB-
TnCasp treated with actinomycin D showed high levels of apoptosis, with 57 and 48 
percent apoptosis positive cells, respectively.  Although pIB-CAT had a higher 
percentage of apoptotic cells, pIB-TnCasp had a higher mean fluorescence, at 92, 
versus only 77 for pIB-CAT.  Cells transfected with dsRNA had both a lower 
percentage of apoptotic cells and mean fluorescence than controls in both the 
presence and absence of actinomycin D (19% and 50, respectively), indicating that 
knockdown of Tn-caspase-1 was effective in reducing the amount of chemically 







Figure 2-7. Fluorscein based TUNEL Staining for overexpression and RNAi silencing of 
Tn-caspase-1. 
Flow cytometry histograms comparing untreated and actinomycin D-exposed cells for each 
condition.  Numbers on the graph represent the percentage of cells considered to be positive 
for apoptosis at that condition and the dashed line represents the fluorescence intensity above 




Tn-caspase-1 activity during baculovirus infection 
 Several previous studies have focused on the activity of Sf-caspase-1 during 
baculovirus infection (Ahmad et al. 1997; Clem 2005; LaCount et al. 2000). 
However, no study has examined in vivo caspase activity at time greater than 3 days 
post infection which is often of interest in protein expression systems.  As such, 
experiments were conducted to determine the activity of Tn-caspase-1 throughout the 
entire course of baculovirus infection.  In addition to cells infected with baculovirus 
(AcMNPV-GFPuv), a group of cells were also transfected 24 hours prior to infection 
with dsRNA against Tn-caspase-1.  Tn-caspase-1 transcript levels and caspase 
activity were analyzed from 1-5 days post infection.  Transcript levels of tn-caspase-1 
remained relatively constant in infected and control (uninfected) cells, but remained 
negligible throughout the entire course of infection for those cells transfected with 
dsRNA (Figure 2-8a and b).  Caspase activity levels, shown in Figure 2-9, of both 
infected and dsRNA cells remained below that of the control for the first 4 days post 
infection.  However, at 5 days post infection, the caspase activity of infected cells 
jumps greatly up to nearly 19 times that of control cells at day 1.  The caspase activity 
of cells transfected with dsRNA also increased, but only to 2.5 times that of the 
control cells at day 1, which was in fact less than the control cells at day 5.  Thus, 
knockdown of Tn-caspase-1 was effective at the protein level during baculovirus 
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Figure 2-8. RT-PCR activity results for cells infected with recombinant baculovirus 
AcMNPV-GFPuv. 
Cells were either uninfected (control), infected, or transfected with dsRNA against Tn-
caspase-1 24h prior to infection.  A, transcript levels of both Tn-caspase-1 and actin for 
infected and infected+dsRNA cells from 1-5 days post infection. B, normalized Tn-caspase-1 
transcript levels for control, infected, and dsRNA treated cells from 1-5 days post infection.  
Normalized transcript level is defined as the Tn-caspase-1 transcript level divided by the tn-
































Figure 2-9. Caspase activity results for cells infected with recombinant baculovirus 
AcMNPV-GFPuv 
Caspase activity of cell lysates measured from 1-5 days post infection.  Activity values are 
normalized to the level of caspase activity in control (uninfected) cells on day 1 post 





Interaction between Tn-caspase-1 and baculovirus protein p35 
 During analysis of the caspase activity during baculovirus infection, it was 
determined that the caspase activity curve (Fluorescence Intensity vs. Incubation 
Time, see Mat. and Meth.) of infected cells became non-linear after about 2 hours of 
incubation (data not shown).  It was unlikely this was due to exhaustion of substrate, 
however, because a similar trend was seen in the caspase activity curves of cells 
transfected with dsRNA, which had a much lower caspase activity.  Since the caspase 
activity curves of cells treated with actinomycin D remained linear, it was likely that 
a baculovirus protein (or proteins) was responsible for this behavior.  A likely choice 
was baculovirus protein p35, which has been shown to be a potent inhibitor of Sf-
Caspase 1 (Ahmad et al. 1997; LaCount et al. 2000).  Futhermore, stable Sf9 cell 
lines producing p35 demonstrated increased resistance to actinomycin D induced 
apoptosis (Lin et al. 2001).  
 In order to determine the effect of baculovirus protein p35 on the activity of 
Tn-caspase-1, High five cells were co-transfected with either pIB-CAT and pIB-p35 
or pIB-TnCasp and pIB-p35 (all plasmid concentrations 2ug/mL).  Caspase activity of 
cell lysates was determined as described previously and is presented in Figure 2-10a.  
In both the presence and absence of actinomycin D, cotransfecting with pIB-p35 
greatly reduced the caspase activity of cells transfected with both pIB-CAT and pIB-
TnCasp.  In fact, at 9 hours of exposure, caspase activity of co-transfected cells is 
well below that of untreated control cells.  At 24 hours of exposure, the caspase 
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Figure 2-10. Caspase activity and Western Blot results for cells transfected with pIB-CAT, pIB-
CAT+pIB-p35, or pIB-TnCasp+pIB-p35 
Cells were transfected with pIB-CAT or contransfected with pIB-CAT+pIB-p35, or pIB-
TnCasp+pIB-p35.  Caspase activity was measured from cell lysates harvested 3 days post 
transfection, in the presence or absence of actinomycin D (9 or 24 hours at 2μg/mL). * - 
indicates a statistically significant (p<0.05) difference between the treated and control values 
at that condition (+ or –actinomycin D). B, Western blot of Tn-caspase-1, all lysates in the 
absence of Actinomycin D.  Lanes are as follows: M. Protein Standard, 1. Crude lysate from 
cells transfected with pIB-CAT and pIB-p35, 2., Crude lysate from cells transfected with 





co-transfected cells, but remains lower than that of cells transfected with only pIB-
CAT or pIB-TnCasp.  It is also important to note that the caspase activity of co-
transfected cells was higher than that of cells transfected with dsRNA. 
 Western Blot analysis was also performed on lysates from co-transfected cells 
(Figure 2-10b), with both groups having similar caspase levels to cells transfected 
with only pIB-CAT.   
     
Tn-caspase-1 and p35 – TUNEL Staining  
Photomicrographs were also taken of co-transfected cells, both in the presence 
and absence of actinomycin D. As with the other treatments, in the absence of 
actinomycin D (Figure 2-11), both groups display normal morphology.  However, 
upon exposure to actinomycin D (24 hours), co-transfected cells both display a 
reduction in apoptotic morphology as compared with cells transfected with only pIB-
CAT or pIB-TncCasp, similar to the effect of dsRNA.  Co-transfected cells were 
analyzed using TUNEL staining to determine if the overall apoptotic level of the cells 
was affected by p35 as it was with dsRNA.  Fluorescent images are shown in Figure 
2-12.  Untreated cells, as before, show little fluorescence, while those cells exposed to 
actinomycin D for 24 hours show strong fluorescence.  Flow cytometry was used to 
quantify the fluorescence, which is shown in Figure 2-13.  Cells co-transfected with 
pIB-CAT and pIB-p35 had 30% apoptosis positive cells with a mean fluorescence of 
50, while cells co-transfected with pIB-TnCasp and pIB-p35 had 34% apoptosis 




data, co-transfection had a lower percentage of apoptosis than cells transfected with 
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Figure 2-11. Photomicrographs for cells transfected with pIB-CAT+pIB-p35 and pIB-
TnCasp+pIB-p35 
Cells were transfected with pIB-CAT or contransfected with pIB-CAT+pIB-p35, or pIB-
TnCasp+pIB-p35.  A, photomicrographs (100x magnification) of either untreated cells or 











Untreated + Actinomycin D
24h
 
Figure 2-12. Fluorscein based TUNEL Staining for cells transfected with pIB-CAT+pIB-p35 and 
pIB-TnCasp+pIB-p35 
Fluorescent micrographs (100x magnification) of either untreated cells or cells exposed to 
actinomycin D for 24 hours (2μg/mL) at each condition. Green fluorescence indicates cells 






Figure 2-13. Fluorscein based TUNEL Staining for cells transfected with pIB-CAT+pIB-p35 and 
pIB-TnCasp+pIB-p35 
Flow cytometry histograms comparing untreated and actinomycin D-exposed cells for each 
condition.  Numbers on the graph represent the percentage of cells considered to be positive 
for apoptosis at that condition and the dashed line represents the fluorescence intensity above 





Tn-caspase-1 is the main effector caspase in T. ni cells 
 Based on the high sequence similarity of Tn-caspase-1 to other lepidopteron 
and mammalian caspases, including the well studied Sf-Caspase-1, it is likely that Tn-
capase-1 behaves in a similar fashion.  Tn-caspase-1, as well as other lepidopteron 
caspases, has the same amino acid sequences (Figure 2-1) as Sf-Caspase-1 at the 
cleavage sites between the prodomain and large subunit (DEGD28↓A), and between 
the large and small subunits (TETD195↓G), and similar sequences at the linker 
cleavage site (DXXD↓G) (LaCount et al. 2000).  Tn-caspase-1 also has a short 
prodomain that is indicative of group II effector caspases.  Furthermore, Tn-caspase-1 
can be detected on a Western blot using an antibody developed for Sf-Caspase-1 
(Figure 2-2), and is cleaved into two subunits upon exposure to actinomycin D.  
Purified Tn-caspase-1-HIS can also be detected on a western both in lysates with and 
without actinomycin D.   
Assuming Tn-caspase-1 is cleaved into two subunits in a manner similar to Sf-
caspase-1, the expected size of the large subunit is 21 kDa with the small prodomain 
and 19 kDa without, while the size of the small subunit would be 12 kDa.  Thus, it 
seems likely that the 21 kDa protein seen on the western blot in Figure 1b is the large 
subunit plus the prodomain, while the 19 kDa protein is the large subunit without the 
prodomain.  Also, since the small subunit of Sf-caspase is not detected by the α-
SfCasp1 antibody (LaCount et al. 2000), it is likely that it does not recognize the 




Further evidence supporting a role similar to Sf-caspase 1 is provided by 
experimental data showing that Tn-caspase-1 must be activated by an apoptotic 
stimuli, in this case actinomycin D, before any upregulation in caspase activity is seen 
(Figure 2-4).  Although overexpression of Tn-caspase-1 can provide a transient 
increase in caspase activity, at 24h exposure to actinomycin D, the caspase activity of 
cells transfected with pIB-TnCasp is no different than that of cells transfected with 
pIB-CAT, suggesting that either the upregulation of native tn-caspase-1 transcription 
as a result of exposure to actinomycin D is greater than the plasmid driven expression 
of tn-caspase-1, or that post-transcriptional regulation of tn-caspase-1 is responsible 
for the increase in caspase activity, or both.  Recent studies have suggested that much 
of the upregulation of Sf-Caspase-1 also occurs post-transcriptionally (Liu and 
Chejanovsky 2006). 
 Since knockdown of tn-caspase-1 via dsRNA eliminates nearly all caspase 3/7 
activity as measured by cleavage of Ac-DEVD-AMC, it is likely that Tn-caspase-1 is 
not only an effector caspase, but is also responsible for the majority of the effector 
caspase activity in High Five cells, as Sf-Caspase-1 is in Sf cells (Ahmad et al. 1997; 
LaCount et al. 2000).  Silencing via dsRNA even reduces the caspase activity of cells 
not exposed to actinomycin D, indicating there is some basal level of caspase activity 
that is reduced in the absence of tn-caspase-1 transcript.   
Tn-caspase-1 activity during baculovirus infection 
During baculovirus infection, the caspase activity of both infected and 
infected+dsRNA cells remained below that of the control for the first 4 days post 




have been shown to inhibit apoptosis in Sf cells (Ahmad et al. 1997; LaCount et al. 
2000; Manji and Friesen 2001).  Further support is given by the fact that 
cotransfecting cells with pIB-p35 greatly reduces caspase activity, both in the 
presence and absence of actinomycin D (Figure 2-10).  However, at 5 days post 
infection and beyond (data not shown), caspase activity greatly increases in infected 
cells, though not in cells transfected with dsRNA against Tn-caspase (Figure 2-9).  To 
our knowledge, no other published study shows caspase activity levels throughout the 
entire course of baculovirus infection.  This data suggests that at a certain point, the 
baculovirus proteins can no longer fully inhibit caspase activity, though the reason for 
this is for the moment unclear.  Perhaps at a certain level, p35 and other baculovirus 
proteins can no longer compete with the upregulation of Tn-caspase-1, resulting in a 
subsequent increase in caspase activity level.  Although differences have been seen in 
the replication of p35 negative baculoviruses with respect to S. frugiperda and T.ni 
derived cell lines (Clem and Miller 1993; Clem et al. 1994; Hershberger et al. 1992) , 
it seems clear that p35 inhibits the principal effector caspase activity in both. 
 
Modulating Caspase Activity – dsRNA vs p35 
 Although both dsRNA and p35 reduce the caspase activity in cells exposed to 
actinomycin D, it is important to contrast their method of action and how this affects 
the reduction in caspase activity.  A model for this modulation is presented in Figure 
2-14.    Transfecting with dsRNA lowers caspase activity through degradation of tn-
caspase-1 mRNA, while p35 presumably acts post-transcriptionaly by preventing Tn-




1997; LaCount et al. 2000).  Further evidence for the post-translational action of p35 
is provided by the fact that Tn-caspase-1 protein levels (as visualized by Western 
Blot, Figure 2-10) are similar in cells with and without p35.  In untreated cells, as 
well as those exposed to actinomycin D for only 9 hours, p35 is more effective at 
reducing caspase activity than dsRNA.  This is likely due to the fact that levels of 
active Tn-caspase-1 are relatively low, allowing p35 to effectively inhibit nearly all 
the Tn-caspase-1 present in the cell.  Alternatively, while dsRNA can substantially 
lower transcript levels, it cannot fully eliminate translation, resulting in a small but 
detectable amount of active caspase.  As apoptosis progresses, the situation is 
reversed.  This is demonstrated in the cells exposed to actinomycin D for 24 hours, in 
which dsRNA is more effective at lowering caspase activity than p35.  This trend is 
also reflected in the flow cytometry data, as the percentage of apoptotic cells in 
dsRNA treated cells is lower than that of cells expressing p35 (Table 2-1).  At this 
point, levels of Tn-caspase-1 may have increased to a level where p35 can no longer 
completely inhibit its cleavage and activation.  However, by lowering transcript 
levels, dsRNA has decreased the amount of caspase available for activation, thereby 
limiting the pool of tn-caspase-1 available for translation.  The difference between 
these situations suggests that the principal form of regulation for Tn-caspase-1 is 
post-transcriptional, which recent studies have suggested is the case for Sf-Caspase-1 
(Liu and Chejanovsky 2006).  It is important to note however, that the performance of 
p35 and dsRNA might change when presented with alternative apoptotic stimuli.  
Since actinomycin D is a transcriptional inhibitor, it may affect p35 in a manner 



















Figure 2-14. Theoretical Model of Caspase Activation and Modulation. 
Tn-caspase-1 can be activated by an apoptotic signal, such as actinomycin-D or baculovirus 
infection.  Once in its active form, Tn-caspase-1 triggers apoptosis.  Both dsRNA and 
baculovirus protein p35 can inhibit caspase activity, but at different steps.  dsRNA directed 
against Tn-caspase-1 works post-transcriptionally, blocking the translation of  Tn-caspase-1 






Table 2-1. Modulating caspase activity with overexpression or RNAi silencing of Tn-
caspase, or through cotransfection with baculovirus protein p35. 
Cells were transfected with either pIB-CAT (control), pIB-TnCasp (overexpression), dsRNA 
synthesized against TnCasp (silencing), pIB-p35, or combinations of the above.  
Actinomycin-D was added three days post transfection, and cells were harvested after the 




 Normalized Caspase Activity (RFU/sec) 
 Untreated 9h Act-D 24h Act-D
pIB-CAT 1.000 ±  0.117 6.863 ±  1.150 14.702 ± 0.265 
pIB-TnCasp 1.054 ±  0.099 12.540 ±  0.516 13.240 ±  0.511 
dsRNA-TnCasp 0.295 ±  0.021 0.985 ±  0.1466 2.276 ±  0.169 
pIB-CAT+pIB-p35 0.086 ±  0.008 0.155 ±  0.059 3.122 ±  0.351 




the exact nature and relative effectiveness of p35 and dsRNA under a wide range of 
apoptotic conditions.        
 
Modulating Caspase Activity and Apoptosis – Implications for Metabolic 
Engineering 
 In addition to modulating caspase activity, both dsRNA and p35 also affect 
the overall level of apoptosis present in cells treated with actinomycin D, as reflected 
in the TUNEL staining and flow cytometry data.  This presents several interesting 
applications for metabolic engineering.  Several studies (Ailor and Betenbaugh 1998; 
Ailor et al. 1997; Arden and Betenbaugh 2004; Figueroa et al. 2005; Figueroa et al. 
2002; Yung et al. 2006a) have used the overproduction of anti-apoptotic proteins in 
order to prolong production time and increase recombinant protein production.  
Relatively few studies have used RNAi to similar effect (Desai and Papoutsakis 1999; 
March and Bentley 2006; March and Bentley 2007; Srivastava et al. 2000; Sung et al. 
2005).  This study has not only demonstrated the potential of using RNAi to decrease 
caspase activity and apoptosis, but has also contrasted some of the differences 
between post-transcriptional (RNAi) versus post-translational (p35) regulation.  In the 
case of Tn-caspase-1, RNAi has proven to be more effective at both decreasing 





Chapter 3 : In vitro and in vivo suppression of Tn caspase-1 
for improved recombinant protein production in High Five 
cell culture with the baculovirus expression vector system 
Abstract 
While traditional metabolic engineering generally relies on the augmentation of 
specific genes and pathways in order to increase the yield of target proteins, the 
advent of RNA interference (RNAi) as a biological tool has given metabolic 
engineers another tool capable of rationally altering the host cell’s biological 
landscape in order to achieve a specific goal.  Given its broad applicability and potent 
specificity, RNAi has the ability to suppress genes whose function is contrary to 
desired phenotype.  In this study, RNAi has been used to increase recombinant 
protein production in a Trichoplusia ni derived cell line (High FiveTM) using the 
Baculovirus Expression Vector System.  The specific target investigated is Tn-
caspase-1, a protease involved in apoptosis that is likely the principle effector caspase 
present in T ni. cells.  Experiments were first conducted using in vitro synthesized 
dsRNA to verify silencing of Tn-capase-1 and increased protein production as a 
result.  Subsequent experiments were conducted using a cell line stably expressing in 
vivo RNAi in the form of an inverted repeat that results in a hairpin upon 
transcription.  Using this construct, Tn-caspase-1 transcript levels were decreased by 
50% and caspase enzymatic activity was decreased by 90%.  This cell line, 
designated dsTncasp-2, demonstrates superior viability under low nutrient culture 
conditions and resulted in as much as 2 times the protein yield when compared to 





In general, metabolic engineering involves altering a gene or regulatory 
network to bring about a desired phenotype (Bailey 1991; Stephanopoulos and 
Vallino 1991).  Traditionally, this has been accomplished either through the 
overexpression of specific targets directly involved in the pathway (Chen et al. 2001; 
Irani et al. 1999)  or alteration of the overall protein machinery, such as the 
expression of chaperone proteins (Borth et al. 2005; Davis et al. 2000; Higgins et al. 
2003; Kitchin and Flickinger 1995; Yokoyama et al. 2000) or transcriptional factors 
(Tigges and Fussenegger 2006) involved in the secretory pathway.  However, as 
illustrated in Figure 3-1a, a similar strategy can be implemented using RNA 
Interference (RNAi) (Hebert et al. 2008a).  First described in 1998 (Fire et al.), RNAi 
involves a broad class of RNA molecules that can be used to suppress or “silence” 
homologous RNA through a pathway that is thought to be conserved throughout 
eukaryotes (Dykxhoorn and Lieberman 2005; Fagard et al. 2000).  The fundamental 
goal of metabolic engineering with RNAi remains the same, though the method of 
execution is different.  Instead of introducing new genes or pathways, potentially 
deleterious genes and pathways are suppressed in an effort to optimize the host’s 
native production machinery.   
With respect to the production of recombinant protein, specific desirable 
phenotypes include the ability to produce a specific product at a high yield and 
quality, as well as the ability to maintain viability in the harsh environments generally 
seen during the production process, including decreased oxygen and nutrients or 




Scott et al. 1992).  Efforts have been made using RNAi to increase protein production 
in Drosophila S2 cells through manipulation of the cell growth cycle (March and 
Bentley 2006; March and Bentley 2007) and in HEK cells through the 
downregulation of transcriptional regulators (Hacker et al. 2004).  Protein quality has 
also been improved using RNAi, both through increased antibody-dependent cellular 
cytotoxicity for anticancer therapeutics (Imai-Nishiya et al. 2007; Kanda et al. 2007; 
Mori et al. 2004), as well as higher sialic acid content in recombinant glycoproteins 
(Ngantung et al. 2006).  Specific past examples of anti-apoptosis engineering 
involving RNAi include enhancing viability and protein production in CHO cells 
through the downregulation of caspase-3 (Lai et al. 2004; Sung et al. 2005) or both 
caspase-3 and caspase-7 (Sung et al. 2007) as well as the suppression of the anti-
apoptotic genes Alg-2 and Requiem (Wong et al. 2006b).  The latter study was the 
second paper in a series that used transcriptional profiling to determine potential 
RNAi targets (Wong et al. 2006a).  A similar screen is underway in HEK cells (Lee et 
al. 2007).     
 RNAi for increasing protein production in the Baculovirus Expression Vector 
System (BEVS) has been less common, despite its high productivity (Caron et al. 
1990; Luckow and Summers 1988; Smith et al. 1985).  Initial reports in Trichoplusi 
ni larvae and Spodoptera frugiperda derived cell lines demonstrated that genes 
produced on a baculovirus could be silenced with RNAi, and subsequent applications 
of this technique aimed to reduce baculovirus infectivity through the downregulation 
of several key genes (Hajos et al. 1999; Isobe et al. 2004; Valdes et al. 2003).  




production in the baculovirus expression vector system, though several examples 
have appeared in both cells and larvae demonstrating the effectiveness of the 
approach (Kramer and Bentley 2003; Lin et al. 2007).     
In a previous work (Kim et al. 2007), we demonstrated that protein production 
in the baculovirus expression vector system could be enhanced using in vitro dsRNA 
against baculovirus genes in Sf9 cells .  Here, we demonstrate that the same principle 
holds true for High Five cells, which have been shown to have superior productivity 
(Davis et al. 1993; Wickham et al. 1992; Wickham and Nemerow 1993).  The 
metabolic engineering target was Tn-caspase-1, which has been shown to be the 
primary effector caspase in High Five cells and an accurate indication of the overall 
level of apoptosis present in the cells (Hebert et al. 2008b).  In this study, we first 
show that protein production can be enhanced by silencing Tn-caspase-1 with 
chemically synthesized in vitro dsRNA (Figure 3-1b).  Further, in order to take 
advantage of the simplicity and robustness of an in vivo approach, we have developed 
a construct for the expression of in vivo dsRNA and subsequently developed the first 
stable T ni. derived cell line in which it is implemented (Figure 3-1c).  The stable cell 
line selected (designated dsTncasp-2) displays a 50% decrease in caspase transcript 
level and a 90% decrease in caspase enzymatic activity during chemically induced 
apoptosis.  dsTncasp-2 also has increased resistance to nutrient starvation and high 
cell densities as is often seen during prolonged suspension culture and demonstrates 
protein production levels up to two-fold that of standard cells.  In order to illustrate 
the generality of this approach, recombinant baculoviruses producing either of the 




acetyltransferase (CAT), were used to compare the production levels of dsTncasp-2 





Figure 3-1. RNAi in Metabolic Engineering and Experimental Design 
A. The goal of RNAi as a metabolic engineering tool is to suppress genes that would divert 
flux away from the product of interest.  Potential target genes include enzymes involved in 
alternative pathways or that degrade the product of interest.  B.  Experimental design – in 
vitro dsRNA and baculovirus infection. dsRNA is first synthesized in vitro from a dsDNA 
template and subsequently transfected into High Five™ cells at a concentration of 1ug/mL.  
The following day, cells are infected with a recombinant baculovirus.  Throughout infection, 
RNA and proteins levels are monitored using RT-PCR and fluorescence measurements. C. 
Experimental design – in vivo dsRNA and baculovirus infection.  Since the dsRNA construct 





Cell culture, transfection, and infection 
Trichoplusia ni BTI-TN-5B1-4 (High FiveTM, Invitrogen) cells were 
cultivated in EX-CELLTM-405 media (SAFC Biosciences) at 27°C. Unless otherwise 
noted, cells were initially plated on 24 well plates at 2×105 cells/mL and transfected 
the following day using FuGene HD® (Roche) according to the manufacturer’s 
procedure.  Briefly, DNA:FuGene complexes at a ratio of 2:7 (ug:uL) were formed in 
distilled and deionized water and then added to the appropriate wells.  For studies 
involving in vitro synthesized dsRNA, 0.5ug was added to each well (concentration 
of 1ug/mL).  In the case of infection with baculovirus, cells were infected 24 hours 
post transfection as previously described with a Multiplicity of Infection (MOI) of 5, 
unless otherwise noted (Kim et al. 2007).    
 
Plasmid Construction and Selection of Stable Cell Line 
 The hairpin construct in pIB-dsTnCasp was created in two steps.  First, the 
sense strand plus a 100bp loop were PCR amplified from pIB-TnCasp (Hebert et al. 
2008b) using the following primers (5' - CGA TCA AAA TGC TGG ACG GTG - 3', 
5' - GAA CCA CGA GTT GTG TTC CTC CAA - 3').  This PCR fragment was then 
TOPO® cloned into pIB/V5-His-TOPO® (Invitrogen), which allows for the insertion 
of gene products under the control of the constitutive Opie-2 promoter and allows for 
the selection of stable cells using blasticidin, creating pIB-TnCasp-Sense.  In a 
separate cloning step, the antisense fragment was first cloned into pCR®-Blunt II-
Topo® (Invitrogen) using the following primers (5' - GCA CCG GTC GAT CAA 




GAA T - 3'), creating pCR-TnCasp-Antisense.  Next, pIB-dsTncasp-Sense and pCR-
dsTnCasp-Antisense were digested using the restriction enzymes AgeI and XhoI, and 
then ligated using T4 DNA Ligase (NEB) to create pIB-dsTnCasp which retains the 
blasticidin resistance gene and contains an insert that will form a RNA hairpin loop 
upon transcription.  To create a stable cell line containing this construct, High Five 
cells were seeded in a 6 well plate at a density of 5x105 cells/mL and transfected with 
2 μg of pIB-dsTnCasp. 2 days post transfection, cells were split at a ratio of 1:5 and 
subject to blasticidin selection at a concentration of 100 μg/mL based on the 
manufacturer’s recommendation.  Several populations that showed resistance to 




A recombinant Autographa californica multiple nucleopolyhedrovirus 
(AcMNPV) that expresses GFPuv or Chloramphenicol acetyltransferase (CAT) under 
the control of the polyhedron promoter was created previosuly (Cha et al. 1999a; Cha 
et al. 1999b; Cha et al. 1999c). The baculovirus was propagated in High FiveTM cells 
(Invitrogen), and Spodoptera frugiperda (Sf-9) cells (Invitrogen) following the 
general protocols outlined in O’Reilly et al.  The titer of baculovirus was determined 
by the endpoint dilution method (O'Reilly et al. 1992).  
 
In vitro dsRNA synthesis 
Total RNA was extracted using RNAqueous (Ambion) according to the 




for 5 minutes, and lysed using the provided lysis/binding buffer.  Following RNA 
isolation, samples were subjected to a DNAse digest as per the manufacturer’s 
instructions in order to remove any contaminating DNA.  First strand templates of 
each target gene were synthesized from 500 ng of total mRNA using oligo-dT 
primers and Superscript RT III (Invitrogen). 700-900 base-pair regions of first strand 
DNA templates were PCR amplified by AccuPrime™ Taq DNA Polymerase High 
Fidelity (Invitrogen) using gene-specific primers for Tn-caspase-1 (5’-CGA TCA 
AAA TGC TGG ACG GTG-3’;5’-AAG TCT GCA TGC ACA GGA AT 3’) or CAT 
(5’-ACT GGA TAT ACC ACC GTT GAT-3’; 5’-GTG CTG GAT ATC TGC AGA 
ATT-3’). T7 sequences (TAA TAC GAC TCA CTA TAG GGA) were added in a 
subsequent PCR step, resulting in T7 templates. To make the dsRNA, sense and anti-
sense RNA was transcribed from T7 templates using the Megascript™ kit (Ambion) 
following the manufacturer’s instructions. The single-stranded RNA (ssRNA) 
synthesized was extracted using phenol/chloroform, resuspended in nuclease free 
water, and then incubated at 65° C for 10 min before cooling to room temperature, 
annealing the two strands to form dsRNA. dsRNA was checked for size and integrity 
using agarose gel electrophoresis and then diluted to a concentration of 3 μg/μL. 
 
Differential display 
 For determining relative transcript levels, RNA was extracted from High Five 
cells using an RNAqueous kit (Ambion) as described above.  RNA concentration was 
determined by measuring the absorbance of a diluted sample at the 260 nanometer 




to reverse transcription using oligodT primers to obtain the first-strand cDNA 
template.  The cDNA template was subject to PCR with sequence-specific primers: 
Tn-caspase-1 (5’-TTC ATT CGA TCC CTG GAT AGC-3'; 5’ TAG TAT CCA GGC 
ACG GTG GAG 3’).  PCR products were run on a 1% agarose gel stained with 
ethidium bromide to compare band intensities under fluorescent light.  Primers 
against a 300 bp section of actin (5'-GAT ATG GAG AAG ATC TGG CA 3’; 5’-
GCG TAG CCC TCG TAG ATG-3’) were used to PCR amplify a loading control 
from the reverse transcript.  Photographs of agarose gels under UV light were taken 
with an AlphaImager® HP and quantitatively analyzed for band intensity using the 
“Spot Denso” function of the AlphaEaseFCTM software package (Alpha Innotech).  
Exposure times were metered to ensure brightness values were not saturated.    
 
Assay of caspase activity  
           After various experimental treatments, cells were collected and washed with 
PBS (pH 7.5). The cells were then suspended in a lysis buffer (from caspase 3 assay 
kit, BD Bioscience) and incubated on ice for 30 min.  Cell debris was removed by 
centrifugation and supernatants were stored for further use or assayed directly. The 
tetrapeptide N-acetyl-Asp.Glu.Val.Asp-7-amino-4-methylcoumarin (Ac-DEVD-
AMC) was used as the substrate. Cell lysates were added to the reaction buffer (from 
caspase 3 assay kit, BD Bioscience) with Ac-DEVD-AMC and incubated for several 
hours at 37°C. The release of AMC was measured using a Spectramax M5 Plate 
Reader (Molecular Devices) (excitation λ380nm, emission λ440nm).  Caspase activity is 





Analysis of GFP Expression 
 GFP fluorescence was measured using a SpectraMax M5 plate reader using an 
excitation wavelength of 395 nm and an emission wavelength of 509 nm.  
Fluorescence was measured in vivo using the well scan method of the SoftMax Pro 
software, which determines well fluorescence by averaging the fluorescence of 21 
distinct points throughout the well.  Thus, each well could be measured non-
invasively and could be used for subsequent time points. 
 
Analysis of CAT Activity 
 For each time point, cells were harvested by sloughing and spun for 5 minutes 
at 500g.  The media was then removed and saved for later analysis, and the cell pellet 
was resuspended in 100uL Cytobuster (Novagen) for 5 minutes.  Cell lysates were 
then spun at 10,000 g for 5 minutes to pellet the insoluble lysates.  Samples were 
either analyzed directly or frozen at -20 °C for later analysis.  CAT was measured in 
both the extracellular media and soluble cell lysates using a colorimetric assay.  A 
reaction mix was prepared consisting of 100uM Acetyl CoA (Sigma) and 1mM 5,5’-
dithiobis-(2-nitrobenzoic acid) in 0.1 M Tris-HCl buffer (pH 7.8).  For each sample, 
200 uL of the reaction mix was added to a well in a 96-well plate and allowed to 
reach 37 °C.  Then, an appropriate amount of sample (extracellular media or lysates) 
was added to the well.  Depending upon the concentration of CAT, samples were 
diluted 5-20 fold in order to fall within the linear range of the assay.  Once the sample 




added to each well and the absorbance (412nm) was measured over a period of 
several minutes.  CAT activity was determined from the initial slope of the plot of 
OD vs. time, and normalized by the amount of crude, undiluted sample. The reported 
CAT activity is a sum of the CAT present in the media and in the cell lysate, scaled 





Results and Discussion 
Silencing Tn caspase-1 via in vitro RNAi – Effects on Recombinant Protein Production 
 
In a previous study (Hebert et al. 2008b), we investigated the behavior of Tn-
caspase-1 both under chemically induced apoptosis and during baculovirus infection.  
In addition to showing that Tn-caspase-1 is presumably the main effector caspase 
present in High Five cells, we demonstrated that the enzymatic activity of Tn-
caspase-1 could be linked to the overall level of apoptosis present in High Five cells, 
and that caspase activity was present during baculovirus infection, especially at 5 
days post infection and longer.  Thus, an initial goal of this study was to see if in vitro 
suppression of Tn caspase-1 increased recombinant protein production in the 
baculovirus expression vector system.  An overall experimental scheme is shown in 
Figure 3-1b.  dsRNA is first synthesized in vitro from dsDNA before it is transfected 
at a concentration of 1 μg/mL into High Five cells that have been seeded in 24 well 
plates the previous day at a density of 1x105 cells/well (2x105 cells/mL).  In addition 
to dsRNA against the target gene, two additional conditions were used; no dsRNA 
and non-specific dsRNA (dsRNA synthesized against CAT).   The day following 
transfection, cells were infected with a recombinant baculovirus.  RNA and protein 
levels were measured during infection using RT-PCR (RNA) and fluorescence (GFP) 
measurements, respectively. 
 In order to determine the effectiveness of the dsRNA against Tn caspase-1, 
total RNA was harvested from each group at 72 hours post infection and analyzed 




and uninfected cells have nearly identical caspase transcript levels, while there is a 
slight decrease (~30%) in cells transfected with non-specific dsRNA against CAT. 
Cells transfected with dsRNA against Tn caspase-1 show a much larger decrease in 
transcript level, at just under 80% when compared to non-transfected cells, 
demonstrating that tn caspase-1 is successfully silenced at the transcriptional level.   
Once suppression at the transcript level was confirmed, a recombinant 
baculovirus producing GFP was used to determine if protein production levels were 
affected by the silencing.  Controls of non-specific dsRNA (dsCAT) and no dsRNA 
(Infected) were included, along with an additional control of only transfection reagent 
(Fugene Only).  As shown in Figure 3-3, all transfection conditions demonstrated 
higher protein levels than non-transfected cells from days 3 to 6.  However, the 
highest protein level at those time points was in cells transfected with dsRNA against 




































Figure 3-2. RT-PCR results from suppression of Tn-caspase-1 via in vitro RNAi during 
baculovirus infection 
Treatment groups included uninfected, infected (no dsRNA), infected + dsRNA against CAT, 
and infected + dsRNA against Tn-caspaase.  A. RT-PCR showing transcript levels of both Tn 
caspase-1 and Actin.  Bands were visualized using ethidium bromide under exposure to UV 
light.  B.  Graphical representation of the relative transcript levels of Tn caspase-1 under all 



































Figure 3-3. GFP production during baculovirus infection  of cells treated with in vitro 
RNAi 
GFP production levels from days 2-6 post infection during suppression of Tn caspase-1 with 
in vitro dsRNA. Treatment groups include uninfected, infected (no dsRNA), infected + 





 Protein levels in Tn caspase-1 suppressed cells were also significantly higher 
than those receiving only transfection reagent or non-specific dsRNA, indicating that 
the increase was indeed due to a sequence specific effect.  This demonstrates that in 
vitro RNAi against Tn caspase-1 is an effective means of increasing recombinant 
protein production in the baculovirus system. 
Development of Tn caspase-1 suppressed cell line 
 Once the beneficial effects of Tn caspase-1 suppression were verified using in 
vitro dsRNA, steps were taken in order to create a cell line capable of expressing in 
vivo dsRNA against Tn caspase-1 in order to reduce any non-specific effects caused 
during the transfection process.  Using the pIB/V5-His-TOPO® plasmid as a 
backbone, a ~600bp region of Tn caspase-1 plus a 100 bp spacer was PCR amplified 
from pIB-TnCasp (Hebert et al. 2008b) and cloned into the vector in sense orientation 
to create pIB-Tncasp-Sense.  The same region was PCR amplified using a different 
set of primers to create pCR-dsTncasp-Antisense, containing the 600bp region of Tn 
caspase-1 in the opposite orientation.  The antisense fragment was then digested using 
the restriction enzymes AgeI and Xho1 and subsequently ligated into pIB-dsTncasp-
Sense, forming pIB-dsTncasp (Figure 3-4). Cells were then transfected with pIB-












Figure 3-4. Plasmid Design 
Plasmid map and detail of the in vivo dsRNA plasmid for the suppression of Tn caspase-1.  
A. Plasmid map of pIB-dsTncasp, which contains a 600bp portion of Tn caspase-1 in the 
sense and antisense orientation separated by a 100bp spacer, all under the control of the 
constitutive Opie-2 promoter.  pIB-dsTncasp also contains a Blasticidin resistance gene under 
the control of the Opie-1 promoter. B.  Detail of the dsRNA construct.  Upon transcription, 
the mRNA transcript folds upon itself, forming a dsRNA hairpin, which is recognized by 





Several populations of Blasticidin resistant cells (designated dsTncasp-1 and 
dsTncasp-2) were then tested for their level of Tn caspase-1 transcription and 
enzymatic activity.  Results are shown in Figure 3-5.  Both dsTncasp-1 and dsTncasp-
2 show a reduction in Tn caspase-1 transcription levels as shown via RT-PCR (Figure  
3-5A). However, dsTncasp-2 has a greater decrease, at 50% versus 40% in dsTncasp-
1 (Figure 3-5B).  This difference is more apparent when examining the level of 
caspase enzymatic activity present in dsTncasp-1 and dsTncasp-2 versus control cells 
(Figure 3-6).  As demonstrated previously, Tn caspase-1 and other caspases have 
minimal activity unless cells are exposed to an apoptotic stimulus, such as the 
chemical apoptosis inducer actinomycin D (Ahmad et al. 1997; Hebert et al. 2008b; 
LaCount et al. 2000).   Thus, the caspase activity of both dsTncasp-1 and dsTncasp-2 
was compared to control cells under normal conditions and after exposure to 
actinomycin D (24 hours at 2 μg/mL). As shown in Figure 3-6, the caspase activity 
levels of untreated cells are similar for each cell line.  However, when treated with 
actinomycin D, the caspase activity of control cells jumps to nearly 70 times control 
levels, while both dsTncasp-1 and dsTncasp-2 show a much smaller increase; 25 and 
7 times control levels, respectively.  In other words, dsTncasp-1 has a 60% decrease 
in caspase activity levels when treated with actinomycin D, while dsTncasp-2 shows 
a nearly 90% decrease when compared to control cells.  So while the level of 
suppression at the transcript level is relatively modest when compared to in vitro 
dsRNA, suppression at the protein level, which is arguably more important, remains 
quite effective.  This large increase in level of suppression when moving from 






































Figure 3-5. In vivo suppression of Tn caspase-1 - RNA Levels 
 
A. RT-PCR of Tn caspase-1 and Actin transcript levels in control High Five cells versus two 
stable cell populations, dsTnCasp-1 and dsTncasp-2.  Bands were visualized using ethidium 
bromide under exposure to UV light.  B.  Graphical representation of the relative transcript 
levels of Tn caspase-1 in standard High Five cells versus stable cell populations, normalized 



































Figure 3-6. In vivo suppression of Tn caspase-1 - Caspase activity levels 
Caspase enzymatic activity of standard High Five cells versus the two stable cell populations.  
Caspase activity was measured from cell lysates in the presence or absence of actinomycin D 






 Because Tn-caspase-1 presumably plays the role of both effecting apoptosis as well 
as activating itself, a given reduction in the available amount of inactive Tn-caspase-1 
would lead to a proportionally greater decrease in the amount of active caspase.  
Since dsTncasp-2 showed a greater level of suppression than dsTncasp-1, it was 
selected for subsequent experiments examining growth, viability, and protein 
production.   
Growth and Viability of Stable cell line 
 Once the suppression of Tn caspase-1 had been verified, experiments were 
conducted in order to test the growth characteristics of dsTncasp-2 against control 
cells.  Both lines were seeded at a concentration of 5x105 cells/mL in 60mm2 culture 
dishes.  A total of four culture conditions were used.  For both control and dsTncasp-
2 cells, one group received 500uL of media each day before counting, while the other 
group received 500uL of PBS (ph 7.4), in order to maintain a consistent culture 
volume.  Cell count and viability was determined each day for 7 days post seeding.  
Results are shown in Figure 3-7.  From days 0-3, all four groups of cells show similar 
growth and viability, but difference between the conditions appear on day 4 and 
beyond.  The viable cell count for control cells, both with and without supplemental 
media, drops sharply from days 4-7.  Cells that did not receive media fare the worst, 
dropping from a count of ~2.6x106 cells at day 3 to ~1.4x106 cells at day 4 and then 
finally to ~6x105 cells at day 7, only just above the number of cells at seeding.  Those 
cells that did receive media fare better than those without, but still drop steadily from 











































Figure 3-7. Cell growth and viability in suspension culture 
Treatment groups included control, control+media, dsTncasp, and dsTncasp+media.  In 
‘+media’ groups, 500uL of fresh media was added each day before counting.  In other 
groups, 500uL of PBS buffer was added each day before counting to maintain a consistent 
volume. A. Viable cell count of each treatment group, determined using a hemocytometer.  B. 




without additional media show greater resilience to the adverse culture conditions.  
dsTncasp-2 cells that only received PBS did decrease in cell count from days 3-7, but 
still maintained a higher cell count than both groups of control cells.  dsTncasp-2 
cells that did receive additional media have similar cell counts from days 4-6, only 
pulling ahead of the PBS cells at day 7.  Viability results show a similar trend.  From 
days 1-3 post seeding, all four groups of cells maintain viability at approximately 
95%.  However, from days 4-7, both groups of control cells show a rapid decline in 
viability, dropping to 24% (PBS) and 58 % (media) on day 7.  In contrast, dsTncasp-2 
cells, especially those that received additional media, maintain higher viability, 
remaining at 65% (PBS) and 82% (media) on day 7.  Since low nutrient 
concentrations can result in apoptosis (Goswami et al. 1999; Mastrangelo and 
Betenbaugh 1998), it is likely that the decreased caspase activity present in the 
dsTncasp-2 cells helps prevent this effect, allowing the cells to maintain higher cell 
count and viability.  The suppression of Tn-caspase-1 seems to me a more effective 
means of preventing cell death than the addition of media.  It is interesting to note 
that while the addition of media clearly benefits both the cell count and viability of 
the control group of cells, the effect was less dramatic in the dsTncasp-2 cells, which 
only showed a significant enhancement of cell count and viability at day 7.  It is 
possible that since dsTncasp-2 cells have a higher tolerance for poor culture 
conditions, it takes a longer time for the lack of media to have a significant impact, 
thus delaying the onset of beneficial effects due to additional media.  Overall, these 
results demonstrate that the silencing of Tn caspase-1 is an effective means of 




Recombinant Protein production with dsTncasp-2 cell line 
 In order to test whether the suppression of Tn-caspase 1 via in vivo dsRNA 
would lead to increased recombinant protein production, both control and dsTncasp-2 
cells were infected with a recombinant baculovirus producing GFP, this time at three 
different MOIs: 0.1, 1, and 10.  Expression levels were measured from days 2-6 and 
are presented in Figure 3-8a.  From days 3-6, GFP levels at all MOIs are significantly 
(p<.05) higher for dsTncasp-2 cells versus control cells, averaging about 1.5 times 
greater at MOI 0.1 and 1 and 2 times greater at MOI 10.    In order to further 
investigate the performance of dsTncasp-2 cells, additional experiments were 
conducted using a recombinant baculovirus that produces Chloramphenicol 
acetyltransferase (CAT).  Both control and dsTncasp-2 cells were again infected at 
MOIs 0.1, 1, and 10.  Results are shown in Figure 3-8b.  Although the difference is 
not as dramatic as with GFP, dsTncasp-2 cells again show higher levels of 
recombinant protein, especially at 6 days post infection, when both MOI 1 and 10 
show a significant increase in CAT production (2.4x and 1.6x respectively). 
Overall, these results demonstrate that suppression of Tn caspase via in vitro dsRNA 
is an effective means of increasing protein production in the baculovirus expression 
vector system.  As such, we successfully created several cell lines expressing a 
dsRNA hairpin that resulted in the constitutive suppression of Tn-caspase 1 at both 
the transcript and protein levels.  Based on its high level of suppression, dsTncasp-2 

































































Figure 3-8. Protein production of dsTnCasp-2 versus control cells with varying MOI 
and a recombinant baculovirus producing either GFP or CAT 
A. GFP production at MOI 0.1, 1.0, and 10 from 2-6 days post infection.  B. CAT production 
at MOI 0.1, 1.0, and 10 from 3-6 days post infection.  GFP was measured in vivo using a 
fluorescence plate reader, while CAT activity was determined using the enzymatic assay 




production.  dsTncasp-2 cells demonstrated an ability to maintain high cell densities 
and viability under low nutrient conditions, as well as superior protein productivity 
upon infection with recombinant baculoviruses producing both GFP and CAT.  
Finally, this work continues to support the application of RNAi in metabolic 
engineering for the improvement of recombinant protein production and the 




Chapter 4 Conclusions and Future Directions 
Conclusions 
Investigation of Tn-caspase-1 in High Five Cells 
 In chapter 2, the novel lepidopteron effector caspase Tn-caspase-1 was 
identified based upon an existing genbank sequence.  While Sf-caspase-1, the primary 
effector caspase in Sf cells, had been well characterized, the same was not true for T. 
ni derived cell lines.  This, coupled with the differences in the infectivity of p35 
negative baculoviruses that have been reported between Sf derived cells and T. ni 
derived cells, warranted an investigation into the nature of caspases in T. ni cells.  
Therefore, in order to further characterize this protein and its function, a vector was 
constructed to overexpress Tn-caspase-1 and chemically synthesized dsRNA was 
used to suppress Tn-caspase-1.  While overexpressed Tn-caspase-1 only temporarily 
increased caspase enzymatic levels during actinomycin D chemically induced 
apoptosis, dsRNA mediated suppression of Tn-caspase-1 resulted in decreased 
caspase enzymatic levels both in the presence and absence of actinomycin D (30 and 
15 percent of control, respectively).  This reduction in caspase activity was 
accompanied by a decrease in the overall level of apoptosis present in the cells, as 
measured by several indicators, including cellular morphology, DNA fragmentation, 
and fluorescent TUNEL staining.  As a result, it became evident that by manipulating 
the level of Tn-caspase-1, one could affect the overall level of apoptosis present in 




 Since Sf-caspase-1 is known to be inhibited by the baculovirus protein p35 
(Ahmad et al. 1997; LaCount et al. 2000; Manji and Friesen 2001), another important 
area of consideration was the behavior of Tn-caspase-1 during baculovirus infection.  
It was discovered that during baculovirus infection, levels of Tn-caspase-1 remained 
below uninfected cells for the first 4 days post infection.  Beyond 4 days, the level of 
Tn-caspase-1 enzymatic activity in baculovirus infected cells increased to nearly 20 
fold the initial level in uninfected cells, though this increase was far less (only 2.5 
fold) in infected cells that had also been treated with dsRNA targeting Tn-caspase-1.  
This data suggests that at a certain point, the baculovirus proteins can no longer fully 
inhibit caspase activity, though the reason for this is at the moment unclear.  Perhaps 
at a certain level, p35 and other baculovirus proteins can no longer compete with the 
upregulation of Tn-caspase-1, resulting in a subsequent increase in caspase activity 
level.   
 In order to more fully investigate the behavior between Tn-caspase-1 and p35, 
a vector was constructed to express p35 in the absence of baculovirus infection.  In 
both the presence and absence of actinomycin D induced apoptosis, expressing p35 
reduced both the caspase activity of cells as well as the overall level of apoptosis.  In 
untreated cells and during the early stages of apoptosis, p35 was more effective than 
dsRNA at decreasing caspase activity levels.  This is likely due to the fact that levels 
of active Tn-caspase-1 are relatively low, allowing p35 to effectively inhibit nearly all 
the active Tn-caspase-1 present in the cell.  Alternatively, while dsRNA can 
substantially lower transcript levels, it cannot fully eliminate translation, resulting in a 




is reversed.  At this point, levels of Tn-caspase-1 may have increased to a level where 
p35 can no longer completely inhibit its cleavage and activation.  However, by 
lowering transcript levels, dsRNA has decreased the amount of caspase available for 
activation, thereby limiting the pool of tn-caspase-1 available for translation.     
It is important to note however, that the performance of p35 and dsRNA might 
change when presented with alternative apoptotic stimuli.  Since actinomycin D is a 
transcriptional inhibitor, it may affect p35 in a manner different than it does dsRNA.  
Thus, further investigation is warranted to determine the exact nature and relative 
effectiveness of p35 and dsRNA under a wide range of apoptotic conditions.        
 
RNAi based suppression of Tn-caspase 1 for increased recombinant protein 
production 
 
 In chapter 3, RNAi based suppression of Tn-caspase-1 is used to enhance 
recombinant protein production in the baculovirus expression system.  Despite its 
high productivity, the baculovirus expression system can be limited by its induction 
of host cell apoptosis and high protease activity.  As demonstrated in chapter 2, RNAi 
based suppression of Tn-caspase-1 leads to not only a decrease in the caspase activity 
level, but also a reduction in apoptosis,  Thus, Tn-caspase-1 became an ideal target 
for increasing recombinant protein production as well.  Initial studies using 
chemically synthesized in vitro dsRNA demonstrated that Tn-caspase-1 transcript 
levels could be reduced by 80 percent, resulting in GFP levels greater than 2 times 
that of untreated cells.  However, some non-specific effects relating to the 
transfection process were observed.  In order to help address this problem as well as 




plasmid was developed containing a construct designed to integrate a dsRNA hairpin 
that could be used to produce in vivo RNAi.  Several populations of cells were created 
using this plasmid and tested for their level of Tn-caspase-1 suppression.  One 
particular cell line, dsTncasp-2, achieved a 50 percent decrease in Tn-caspase-1 
transcript levels, which resulted in a nearly 90 percent decrease in caspase enzyme 
activity during actinomycin D induced apoptosis.  dsTncasp-2 was also tested for its 
ability to remain viable under low nutrient growth conditions and demonstrated 
superior viability when compared to standard High Five cells.  Finally, dsTncasp-2 
demonstrated increased recombinant protein production using two different model 
proteins, GFP and CAT, resulting in as much as twice the production of control cells.        
RNAi as a metabolic engineering tool 
One of the main goals of this project was to further the Bentley lab’s 
application of RNAi as a tool for metabolic engineering, specifically through the 
application of in vivo RNAi.  While traditional metabolic engineering generally adds 
new proteins or pathways, RNAi can present a more nuanced approach capable of 
optimizing the host natural protein production system by taking advantage of pre-
existing regulatory mechanisms or pathways.  Although research in RNAi has 
certainly exploded in the medical arena as a next generation therapeutic, it has seen 
relatively little use in metabolic engineering, resulting in opportunities for further 
research, some of which are discussed below.  As RNAi technology continues to 





Bacterial expression of Tn-caspase-1 
 In order to conduct in vitro studies with Tn-caspase-1, it must be effectively 
produced and purified.  Although Tn-caspase-1-HIS was produced in High Five cells, 
it proved difficult to produce large amounts of pure activated Tn-caspase-1-HIS due 
to the background of native Tn-caspase-1.  Thus, expression in bacterial systems was 
conducted using the pTrcHis vector system in the TOP10 strain of E. coli.  While an 
approximate yield of 0.5 mg/mL was achieved as measured by UV absorbance and 
the Bradford assay, no measurable caspase activity was detected.  However, literature 
results and personal communications indicate that the expression of active caspases, 
including Sf-caspase-1, in E. coli is possible using the BL21 production strain and the 
pET200 vector system.  Thus, if future studies require active in vitro Tn-caspase-1, 
production should be attempted using those conditions.      
Tn-caspase-1 and baculovirus proteins p35 and FP-25   
 The major difference between Sf versus T. ni derived cell lines is their 
behavior when infected with p35 negative baculoviruses.  In Sf derived cell lines, 
infection with a p35 negative baculovirus prevents both protein production and virus 
replication, while viruses replicate normally in T. ni derived cells (Clem and Miller 
1993).  Recent studies have shown that baculoviruses lacking both p35 and another 
protein, FP-25, have resulted in apoptotic characteristics in TN-368 cells, suggesting 
it also interacts with apoptotic proteins in lepidopteron cells.  It would be interesting 




interactions with both p35 and FP-25 in vitro, and the kinetics and stoichoimetry of 
Tn-capase-1 – baculovirus protein interactions.    
   
Additional RNAi targets and host systems   
While Tn-caspase-1 proved to be an effective metabolic engineering target, an 
additional goal would be to develop a cell line in which several genes were 
suppressed simultaneously.  This could potentially further increase a cell line’s ability 
to cope with the stresses associated with recombinant protein production in general 
and baculovirus infection in particular.  However, one of the difficulties in working 
with lepidopteron cell lines is the relative lack of genomics data to widely screen and 
identify novel targets.  Thus, such a technique could be attempted in either 
Drosophila S2 cells, or HEK293 (Human Embryonic Kidney) cells.  HEK293 cells 
have emerged as a promising cell line for recombinant protein production (Han et al. 
2007; Sun et al. 2006), including adeno-associated virus particles (Hildinger et al. 
2007). This, coupled with the vast amount of human sequence data and readily 
available microarrays would make HEK293 cells an excellent choice for such a study. 
Drosophila S2 cells have been used in the past by the Bentley lab and others for the 
production of recombinant protein (March and Bentley 2006; March and Bentley 
2007; McCarrol and King 1997), are genetically well characterized, and also have 
readily available microarrays.  By taking advantage of these additional genetic tools, 




Target identification and implementation strategies 
One method for identifying new targets would be to expose cells to a number 
of focused stresses designed to simulate the conditions faced during recombinant 
protein production, coupled with corresponding microarray analysis to determine 
which genes are up- and down-regulated during this process.  Through the exposure 
of cells to focused stresses including hypoxia, ER stress, and apoptosis and then 
subjecting them to a time dependent microarray analysis, genes associated with the 
presence of abnormal proteins and their processing could be identified.  In order to tie 
transcriptional data to the desired phenotype (increased recombinant protein 
production); several “stressing” strategies will be linked to protein expression using 
reporter cell lines created in the Bentley lab that express red fluorescent markers 
(DsRed or HcRed) and a secreted product, human interleukin-2 (IL-2) (Yung et al. 
2006b).  Cells could be sorted based on their fluorescence and used to determine the 
transcriptional landscape present during the high production of recombinant protein.  
Genes that are differentially expressed could then be selected as metabolic 
engineering targets for either RNAi or overexpression. 
Since the Bentley lab has previously demonstrated the importance of tuning 
the level of RNAi based suppression (March and Bentley 2007) and increasing cell 
growth rate through RNAi (March and Bentley 2006), one could envision a 
production scheme for first improving growth rate of cells through the suppression of 
a specific set of genes, such as cell growth and metabolic regulators, and then 
transitioning cells into a production mode in which a different set of genes is targeted, 




stresses and subsequent microarray analysis, these key regulators could be identified 
and implemented in a dynamic and focused manner to increase recombinant protein 
production.        
 
 
Figure 4-1. Regulating multiple RNAi targets throughout the production cycle. 
 In order to maximize the potential of RNAi as metabolic engineering tool, targets will be 
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Figure 5-1.  DNA laddering following exposure to actinomycin D. 
2 ug of DNA was run on a 1.5% agarose gel and visualized using UV light. The lanes are as 
follows: C - control/no actinomycin D, 1 - actinomycin D at a concentration of 1 ug/mL, 2 - 
0.5 ug/mL, 3 - 0.25 ug/mL, 4 - 0.1 ug/ mL, 5 - 0.05 ug/mL.  Actinomycin D was added for a 



























Figure 5-2. Viable cell count following exposure to actinomycin D. 
Cells were seeded at a density of 250,000 cells/mL and grown for 24 hours before the 
addition of 2 ug/mL actinomycin D (indicated by the arrow). Viable cell count was 
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Figure 5-3. Cell labeling 
Cells were exposed to actinomycin D for 24 hours and then labeled using the Vybrant® 
Apoptosis Assay Kit #4 (Invitrogen), which labels necrotic cells red using Propidium Iodide 
and apoptotic cells green using YO-PRO®-1. Pictures were taken at 100x magnification and 
identical exposure lengths.  Cells were either untreated or exposed to actinomycin D (24 
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